meglumine antimoniate has been researched along with Leishmaniasis, Cutaneous in 399 studies
*Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.75) | 18.7374 |
| 1990's | 38 (9.52) | 18.2507 |
| 2000's | 133 (33.33) | 29.6817 |
| 2010's | 167 (41.85) | 24.3611 |
| 2020's | 58 (14.54) | 2.80 |
| Authors | Studies |
|---|---|
| Conceição-Silva, F; de Mello, CX; Fagundes, A; Lyra, MR; Martins, ACDC; Miranda, LFC; Mouta-Confort, E; Oliveira, LFA; Oliveira, RVC; Oliveira-Ribeiro, C; Pimentel, MIF; Quintella, LP; Schubach, AO; Valete-Rosalino, CM; Vasconcellos, ÉCFE | 1 |
| Al-Mohammed, HI; Seif, MA | 1 |
| Clevenbergh, P; Mervillie, K; Mostmans, Y; Richert, B; Van Gysel, J; Vanden Nest, H | 1 |
| Alvarez, F; Arana, B; Boni, M; Echevarria, J; Jiménez, A; Llanos-Cuentas, A; López, L; Méndez, C; Quintero, J; Ramos, AP; Rode, J; Tabares, Y; Valencia, B; Vélez, I | 1 |
| Alahdin, S; Almani, PGN; Babaei, Z; Bamorovat, M; Keyhani, A; Mohseni, F; Mostafavi, M; Nave, HH; Oliaee, RT; Salarkia, E; Sarlak, M; Sharifi, F; Sharifi, I; Tavakoly, R | 1 |
| Berman, J; Cayhuara, E; Gutiérrez, P; Molina, C; Paz, D; Sánchez, M; Soto, J; Soto, P | 1 |
| Andreazza Costa, MC; Borsodi, MPG; Cabral Abreu Grijó, B; Castro Ferreira, MM; Costa, AV; Lima, WP; Rodrigues Gazolla, PA; Rossi Bergmann, B; Teixeira, RR | 1 |
| Dayer, MS; Ghaffarifar, F; Sherafati, J | 1 |
| Aflatoonian, MR; Bahrami, M; Eskandari, SE; Fekri, A; Firooz, A; Ghoorchi, M; Javadi, A; Khamesipour, A; Khatami, A; Sharifi, I | 1 |
| Almani, PGN; Bamorovat, M; Salari, S; Sharifi, I | 1 |
| Chiheb, S; Dahbi, HS; Darif, D; El Idrissi Saik, I; Fatoiki, FZE; Hali, F; Hammi, I; Kihel, A; Riyad, M; Soussi Abdellaoui, M; Tazi Saoud, Z | 1 |
| Aounallah, A; Belajouza, C; Denguezli, M; Lahouel, M; Manaa, L; Mkhinini, H; Salah, NB | 1 |
| Afshari, F; Eskandari, S; Firooz, A; Jaafari, M; Javadi, A; Khamesipour, A; Mohammadi, A; Mortazavi, H; Tasbihi, M | 1 |
| Barbosa, JS; Barroso, DH; da Motta, JOC; Freire, GSM; Gomes, CM; Gonçalves, RT; Sampaio, RNR | 1 |
| Bacellar, O; Carvalho, EM; Fraga, D; Guimarães, LH; Lago, E; Lago, J; Lago, T; Silva, YJ; Werneck, GL | 1 |
| Carvalho, AG; Carvalho, CDP; Carvalho, RDP; Dias, JVL; Luz, JGG; Pires, HHR | 1 |
| Botella-Estrada, R; Garcías-Ladaria, J; Martínez-Doménech, A; Mateu-Puchades, A; Nadal-Lladó, C; Palacios-Diaz, RD; Quintero, A; Rocamora-Durán, V; Sahuquillo-Torralba, A; Salavert-Lleti, M; Santos-Alarcón, S; Unamuno-Bustos, B; Vila-Payeras, A | 1 |
| Darchini-Maragheh, E; Derakhshan, Z; Mashayekhi Goyonlo, V | 1 |
| Amato, VS; Cota, G; França, AO; Francesconi, F; Hueb, M; Lyra, MR; Oliveira, LFA; Oliveira, RVC; Pimentel, MIF; Pompilio, MA; Rodrigues, BC; Sampaio, RNR; Schubach, AO; Silva, RE; Souza, RM; Valete, CM | 1 |
| Aronson, NE; Billick, K | 1 |
| Azizi, H; Hataminejad, M; Khamesipour, A; Mahdavinik, E; Montazeri, S | 1 |
| Ahmadi, O; Dehghani, F; Farhadian, N; Mashayekhi Goyonlo, V | 1 |
| Ezzatkhah, F; Ghasemian Yadegari, J; Khudair Khalaf, A; Mahmoudvand, H; Mohammadi, HR; Shakibaie, M | 1 |
| Aroosh, A; Fatima, A; Hayat, O; Islam, A; Naz, S; Ozbel, Y; Raza, N; Toz, S; Waseem, S | 1 |
| Almeida-Souza, F; Alves, CR; Bourguignon, SC; Cysne-Finkelstein, L; da Silva Calabrese, K; de Castro Côrtes, LM; Ferreira, VF; Gonçalves-Oliveira, LF; Lechuga, GC; Santini Pereira, BA; Souza-Silva, F; Veloso, LB | 1 |
| Bahrami, S; Bemani, E; Oryan, A | 1 |
| Boumezzourh, A; Chiheb, S; Dessay, M; Elfatoiki, FZ; Elkhalfaoui, N; Maksouri, H; Riyad, M | 1 |
| Eid Rodríguez, D; Pulkki-Brännström, AM; San Sebastian, M | 1 |
| Gholami, E; Habibzadeh, S; Heidari-Kharaji, M; Khadir, F; Oryan, A; Rafati, S; Taheri, T; Zahedifard, F | 1 |
| Brito, NC; Cota, G; Machado de Assis, TS; Rabello, A | 1 |
| Botella-Estrada, R; Castro-Hernández, I; Chouman-Arcas, R; Garrido-Jareño, M; Gómez-Ruiz, MD; Llavador-Ros, M; López-Hontangas, JL; Molina-Moreno, JM; Pemán-García, J; Sahuquillo-Torralba, A; Salavert-Lleti, M | 1 |
| Bonvoisin, T; Carvalho, EM; Carvalho, LP; Guimarães, LH; Machado, PRL; Rocha, PN; Suprien, C; Teixeira, M | 1 |
| Aguiar, MG; Cota, G; da Silva, RE; Fernandes, HJ; Ramalho, DB; Silveira, JN | 1 |
| Alcoba, G; Blaizot, R; Cissé, H; Couppie, P; Demar, M; Ginouves, M; Prevot, G; Senchyna, A; Simon, S | 1 |
| Aragão Horoiwa, T; Bandeira, CL; Cerize, NNP; Cortez, M; de Oliveira, AM; Migotto, A; Sauter, IP | 1 |
| Abtahi, M; Ahmadian, S; Boozhmehrani, MJ; Cavallero, S; Eslami, G; Hosseini, SS; Khamesipour, A; Vakili, M | 1 |
| Çavuş, İ; Harman, M; Kaya, T; Özbilgin, A; Yıldırım, A | 1 |
| Alsina, M; Fuertes, I; Giavedoni, P; Marti-Marti, I | 1 |
| Alves, J; Barreiros, H; Bonito, F; Costin, A | 1 |
| Eljure-López, N; Ilizaliturri-Flores, I; Leal-Ascencio, VJ; Proy-Trujillo, H; Villela-Segura, U | 1 |
| Layegh, P; Mashayekhi Goyonlo, V; Morovatdar, N; Nahidi, Y; Tafazzoli, Z | 1 |
| Benzekri, L; Hassam, B; Ismaïli, N; Lakhmiri, M; Maouni, S; Meziane, M; Senouci, K; Znati, K | 1 |
| Aragão Macedo, SR; de Azevedo Calderon, L; de Barros, NB; do Nascimento, JR; Fernandes do Nascimento, FR; Ferreira, ADS; Lourenzoni, MR; Moreira Dill, LS; Nicolete, R; Soares, AM; Valentim Silva, JR; Zanchi, FB | 1 |
| Akyar, I; Çavuş, İ; Çulha, G; Ertabaklar, H; Gündüz, C; Güray, MZ; Harman, M; Özbel, Y; Özbilgin, A; Zeyrek, FY | 1 |
| Carranza, A; Polanco Garcia, M | 1 |
| Alexander, N; Cossio, A; Giraldo-Parra, L; Gómez, MA; Gore Saravia, N; Navas, A; Prieto, MD | 1 |
| Elias, VM; Osorio-Arango, K; Pinart, M; Pinzón-Flórez, CE; Reveiz, L; Romero, GA; Rueda, JR; Silveira Maia-Elkhoury, AN; Tweed, JA | 1 |
| Cruz, FF; da Fonseca-Martins, AM; da Silveira Pratti, JE; de Araujo, AF; de Matos Guedes, HL; Diaz, BL; Dos-Santos, JS; Firmino-Cruz, L; Freire-de-Lima, CG; Maciel-Oliveira, D; Ramos, TD; Rocco, PRM; Silva, JD; Tenorio, JIN | 1 |
| Bartoloni, A; Bartolozzi, D; Corsi, P; Di Muccio, T; Gramiccia, M; Spinicci, M; Trotta, M; Zammarchi, L | 1 |
| Abbasi Shaye, Z; Ghanizadeh, S; Layegh, P; Salehi, M; Zabolinejad, N | 1 |
| Ali, SA; Behmanesh, MA; Eslaminejad, MB; Haddad, MHF; Navard, SH; Nourian, A; Rezvan, H | 1 |
| Çavuş, İ; Gündüz, C; Harman, M; Özbilgin, A; Tunalı, V; Turgay, N | 1 |
| Abdellahi, L; Amirmozafari, N; Hejazi, SH; Sotoodehnejadnematalahi, F | 1 |
| Barral-Netto, M; Carvalho, EM; Costa, B; de Jesus, DV; Doria, SS; Guerra, JO; Guerra, MDGB; Machado, PRL; Mendes, L; Ortiz, J; Penna, G; Silva, ASD; Silva, GVD | 1 |
| Bamorovat, M; Davoudi, N; Ghasemi Nejad Almani, P; Kazemi, B; Khosravi, A; Salari, S; Salarkia, E; Sezavar, M; Sharifi, I | 1 |
| Alvarado, MT; Cantillo-Barraza, O; Correa-Cárdenas, CA; Cruz, C; Duque, MC; Méndez, C; Patino, LH; Pérez, J; Ramírez, JD; Rodríguez, O; Romero, Y | 1 |
| Aguiar, MG; Araújo, RS; Barros, ALB; da Conceição, EC; de Oliveira, LG; Fernandes, AP; Fernandes, CP; Ferreira, LAM; Kawakami, MYM; Oliveira, AEMFM; Queiroz-Junior, CM; Ricotta, TQN; Zamora, LO | 1 |
| Barrio, A; Beckar, J; Delgado-Noguera, LA; García-Bustos, MF; González-Prieto, G; Hashiguchi, Y; Jaime, D; Lemir, CG; Monroig, S; Mora, MC; Moreno, S; Paniz-Mondolfi, AE; Parodi, C; Ramos, F; Ruiz-Morales, L | 1 |
| Aflatoonian, MR; Amiri, R; Bamorovat, M; Borhani Zarandi, M; Dabiri, S; Hassanzadeh, S; Heshmatkhah, A; Karamoozian, A; Kheirandish, R; Shamsi Meymandi, S; Sharifi, F; Sharifi, I | 1 |
| Carvalho, AM; Carvalho, EM; Carvalho, LP; Castellucci, L; Guimarães, LH; Lago, A; Lago, J; Lago, T; Nascimento, M | 1 |
| Darchini-Maragheh, E; Goyonlo, VM; Kiafar, B; Layegh, P; Tayyebi, M | 1 |
| Braz, LMA; Celeste, BJ; Goto, H; Lindoso, JAL; Oyafuso, LKM; Ramos-Sanchez, EM; Reis, LC; Yamashiro-Kanashiro, EH | 1 |
| Castro, MDM; Cossio, A; Osorio, L; Velasco, C | 1 |
| Bartlett, AH; Berger, BA; Castro, MDM; Cossio, A; Pho, MT; Prada, S; Saravia, NG | 1 |
| Ayatollahi, J; Bafghi, AF; Shahcheraghi, SH | 1 |
| Godarzi, H; Heiran, A; Saki, N | 1 |
| Antônio, LF; Bedoya-Pacheco, SJ; Fagundes, A; Lyra, MR; Madeira, MF; Marzochi, MCA; Mouta-Confort, E; Passos, SRL; Pimentel, MIF; Ribeiro, MN; Saheki, MN; Salgueiro, MM; Santos, GPLD; Schubach, AO; Valete-Rosalino, CM; Vasconcellos, ÉCFE | 1 |
| Kazuma, FJ; Membrive, NA; Reinhold-Castro, KR; Silveira, TGV; Teixeira, JJV; Teodoro, U | 1 |
| Anversa, L; Batista, LR; Cuba, MB; Dias da Silva, VJ; Martins, TY; Nogueira Nascentes, GA; Ramirez, LE; Richini Pereira, VB; Ruiz, LDS; Salles Tiburcio, MG | 1 |
| García, M; Monzote, L; Satyal, P; Scull, R; Setzer, WN | 1 |
| Brito, NC; Cota, GF; Rabello, A | 1 |
| da Silva Pacheco, R; de Fatima Madeira, M; de Oliveira Schubach, A; Fernandes Pimentel, MI; Gagini, T; Maria Valete-Rosalino, C | 1 |
| Calvopiña, M; Cevallos, W; Flores, J; Loor, R; Padilla, J; Paredes, Y; Puebla, E | 1 |
| Antônio, LF; Brahim, LR; Costa, ADD; Dias, CMG; Duque, MCO; Lyra, MR; Marzochi, MCA; Paes, LEC; Pimentel, MIF; Schubach, AO; Valete-Rosalino, CM; Vieira, IF | 1 |
| Cedeño, DL; Fernandez, M; Jones, MA; Murillo, J; Ocampo-Cardona, R; Ríos-Vásquez, LA; Robledo, SM; Velez, ID | 1 |
| Carvalho, JP; Cota, E; Cota, G; Moreira, HSA; Rabello, A; Ramalho, DB; Senna, MCR; Silva, RED | 1 |
| Bruno, O; Denis, S; Ihcene, KD; Khatima, AO; Naouel, E; Razika, B; Sofiane, B; Zoubir, H | 1 |
| Hanafi, Y; Oubaaz, A | 1 |
| Aydın Teke, T; Gayretli Aydın, ZG; Kaman, A; Metin, Ö; Mungan, M; Öz, FN; Tanır, G | 1 |
| Robledo, SM; Schmidt, TJ; Vélez, ID | 1 |
| Costa, AC; Costa, RMR; da Silva, ICM; da Silva, SHM; Dias, CGBT; Farias, LHS; Gélvez, APC; Pereira, VS; Rodrigues, APD | 1 |
| Cardona-Arias, JA; López-Carvajal, L; Tamayo-Plata, MP; Vélez, ID | 1 |
| Abbas, D; Masoud, D; Moein, D; Saeed, M | 1 |
| Bordignon, J; Conchon Costa, I; Costa, IN; da Silva, SS; Fanti, JR; Felipe, I; Mizokami, SS; Pavanelli, WR; Verri, WA | 1 |
| David, JR | 1 |
| Afgar, A; Asadi, A; Bamorovat, M; Daneshvar, H; Heshmatkhah, A; Jafarzadeh, A; Kareshk, AT; Mohammadi, MA; Oliaee, RT; Sharifi, I | 1 |
| Çavuş, İ; Ertabaklar, H; Kaya, T; Özbilgin, A; Yıldırım, A | 1 |
| Avelar, DM; Cota, G; Moreira, HSA; Pedras, MJ; Rabello, A; Ramalho, DB; Saraiva, L; Senna, MCR; Silva, RED | 1 |
| Cortes, C; Cuestas, D; Forero, Y; Galvis, I; Mora, S; Motta, A; Peñaranda, E; Pérez, C; Puentes, J; Velasquez, O | 1 |
| Aouam, K; Boughattas, NA; Brahim, HB; Chaabane, A; Chadli, Z; Chakroun, M; Fredj, NB; Romdhane, HB | 1 |
| Abedi, L; Afgar, A; Babaei, Z; Bamorovat, M; Jafarzadeh, A; Kareshk, AT; Keyhani, A; Oliaee, RT; Sharifi, F; Sharifi, H; Sharifi, I | 1 |
| Akhoundi, B; Ebrahimzade, E; Elikaee, S; Khalili, S; Mohammadi-Yeganeh, S; Mohebali, M; Moosazadeh Moghaddam, M; Sharifi-Yazdi, MK; Shayan, P | 1 |
| Castro, MDM; Cossio, A; Dávalos, D; Desai, MM; Uribe-Restrepo, A | 1 |
| Aflatoonian, MR; Bamorovat, M; Fekri, A; Heshmatkhah, A; Keyhani, A; Khosravi, A; Mostafavi, M; Naderi, A; Oliaee, RT; Parizi, MH; Sharifi, I; Varma, RS | 1 |
| Fernández, OL; Gómez, MA; Martínez-Salazar, B; Regli, IB; Saravia, NG; Tacchini-Cottier, F | 1 |
| Carvalho, GB; Carvalho, SH; Frézard, F; Moura, AS; Pereira, NP; Ramos, LMQC; Rocha, MOC | 1 |
| Aflatoonian, MR; Afshar, AA; Arefinia, N; Bamorovat, M; Keyhani, A; Khatami, M; Khosravi, A; Mostafavi, M; Oliaee, RT; Parizi, MH; Sadeghi, B; Shafiian, A; Sharifi, I | 1 |
| Enokihara, MMSS; Gregorio, AW; Guerra, JM; Nonogaki, S; Tomimori, J; Vasconcellos, MRA | 1 |
| Farajzadeh, S; Kakooei, S; Keyhani, A; Khazaeli, P; Mostafavi, M; Parizi, MH; Sharifi, H; Sharifi, I | 1 |
| de Almeida Marzochi, MC; de Camargo Ferreira E Vasconcellos, É; de Fátima Antonio, L; de Oliveira Duque, MC; de Oliveira Schubach, A; Horta, APA; Magalhães, RS; Paes, LRB; Pimentel, MIF; Quintão Silva, JJ; Rosandiski Lyra, M; Saheki, MN; Soares, PAO; Valete-Rosalino, CM | 1 |
| Fallah, M; Jaafari, MR; Moosavian, SA | 1 |
| Bari, AU; Khan, NH | 1 |
| Barroso, PA; Bracamonte, E; Cajal, P; Hashiguchi, Y; Hoyos, CL; Korenaga, M; Lauthier, JJ; Marco, JD; Quipildor, M; Uncos, A | 1 |
| Alipour, A; Hosseinzadeh, A; Iranpour, S | 1 |
| Arboleda, M; Barrantes, S; Robledo, SM; Úsuga, LY | 1 |
| Aflatoonian, B; Aflatoonian, MR; Aghaei Afshar, A; Arefinia, N; Babaei, Z; Bamorovat, M; Farajzadeh, S; Fekri, A; Ghasemi Nejad Almani, P; Gouya, MM; Heshmatkhah, A; Khamesipour, A; Khatami, M; Khosravi, A; Mohammadi, MA; Mohebali, M; Salarkia, E; Sharifi, F; Sharifi, H; Sharifi, I; Shirzadi, MR; Varma, RS | 1 |
| Abbas, D; Mahmood, N; Masoud, D; Moein, D | 1 |
| Layegh, P; Mashayekhi Goyonlo, V; Nahidi, Y; Najaf Najafi, M; Taghavi, F | 1 |
| Marques, MEA; Marques, SA; Merlotto, MR; Ramos, PM | 1 |
| Cupolillo, E; Dávila, AM; Ribeiro-Alves, M; Romero, GA; Torres, DC | 1 |
| Barbosa, H; Delgado, G; Gutiérrez, J; Pinzón, J; Vallejo, B | 1 |
| Behnaz, F; Golshan, Z; Mohammadzadeh, M | 1 |
| Emami, S; Momeni, A; Navaei, A; Rafienia, M; Rasoolian, M | 1 |
| Dowlati, Y; Firooz, A; Khamesipour, A; Khatami, A; Mehryan, P; Rahshenas, M; Talaee, R; Tehrani, S | 1 |
| Blum, JA; Hatz, C; Mosimann, V; Neumayr, A | 1 |
| Amorim, FM; Barbosa-Filho, JM; Caldas, JP; Leite, JA; Néris, PL; Oliveira, MR; Rodrigues, LC; Rodrigues, YK; Rodrigues-Mascarenhas, S | 1 |
| Calvopiña, M; Hashiguchi, Y; Martinez, L | 1 |
| Botella Estrada, R; Escutia Muñoz, B; Torres Garcia, Y | 1 |
| Lenvers, P; Marty, P; Peyron, F | 1 |
| Barnadas, MA; Català, A; Muñoz, C; Puig, L | 1 |
| Borges-Costa, J; Campino, L; Filipe, P; Lopes, L; Soares-Almeida, L; Vasconcelos, P | 1 |
| Jazayeri, SB; Shahlaee, A | 1 |
| Arboleda, M; Díaz, A; Jaramillo, L; Ortiz, D | 1 |
| Ghazizadeh, F; Jaafari, MR; Jabini, R; Karimi, G; Khamesipour, A; Vahdati Hasani, F | 1 |
| Aoun, K; Bouratbine, A | 1 |
| Cesetti, MV; de Morais, OO; Gomes, CM; Mendes, MS; Roselino, AM; Sampaio, RN | 1 |
| Abbasi, A; Bavarsad, N; Fallah, M; Feizi, E; Jaafari, MR; Kalat, SA; Khamesipour, A; Khashayarmanesh, Z; Neghabi, K | 1 |
| Khamesipour, A; Khatami, A; Mortazavi, H; Soori, T; Vasheghani-Farahani, A | 1 |
| Attarwala, S; Saleem, M; Talat, H | 1 |
| Aoun, K; Benikhlef, R; Bouratbine, A; Faraut, F; Harrat, Z; Jeddi, F; Marty, P; Mary, C; Piarroux, R; Pomares, C; Pratlong, F | 1 |
| Barrio, A; Basombrío, MA; Cardozo, RM; Cimino, RO; de Raspi, EM; García Bustos, MF; Parada, LA; Parodi, C; Prieto, GG; Soto, J; Uncos, DA; Yeo, M | 1 |
| Fernández-Crehuet, P; Ruiz-Villaverde, R | 1 |
| Berry, A; Charafeddine, K; Ghosn, N; Habib, RH; Issa, G; Khalifeh, H; Khalifeh, I; Rady, A; Saroufim, M | 1 |
| Kutlubay, Z; Polat, E | 1 |
| Baba, N; Boui, M; Frikh, R; Hjira, N; Lamsyah, H; Marcil, T; Oumakhir, S | 1 |
| Alsina Gibert, M; Estrach, T; Fuertes, I; Giavedoni, P; Iranzo, P | 1 |
| Bhattacharjee, H; Charret, KS; Mandal, G; Mandal, S; Mukhopadhyay, R; Papadopoulou, B; Sharma, M | 1 |
| El Benaye, J; El Haouri, M; Miloudi, M | 1 |
| Bertho, ÁL; Cunha, CF; Da-Cruz, AM; Ferraz, R; Gomes-Silva, A; Lyra, MR; Mendonça, SC; Pimentel, MI; Schubach, AO; Valete-Rosalino, CM | 1 |
| Awan, MM; Jamal, Q; Khan, NH; Shah, A; Sutherland, C; Wahid, S | 1 |
| Aksoy, M; Özbilgin, A; Sürücü, HA; Turan, E; Yeşilova, Y | 1 |
| Cardona-Arias, JA; López-Carvajal, L; Vélez, ID | 1 |
| Barati, DA; Bojd, MS; Hemmati, M; Karamian, M; Salehabadi, A | 1 |
| Aydın Teke, T; Bayhan, Gİ; Gayretli Aydın, ZG; Metin Timur, Ö; Mungan, M; Öz, N; Tanır, G; Yılmaz, N | 1 |
| Aksoy, M; Ardic, N; Oghumu, S; Satoskar, AR; Surucu, HA; Yesilova, A; Yesilova, Y | 1 |
| Ishkhanian, S; Shanehsaz, SM | 1 |
| de Barros, NB; de Figueiredo Nicolete, LD; Ferreira, Ados S; Macedo, SR; Nicolete, R | 1 |
| Ahmadi, F; Bahrami, S; Esmaeilzadeh, S; Zarei, M | 1 |
| Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B | 1 |
| El kartouti, A; Elbenaye, J; Miloudi, M | 1 |
| Aksakal, M; Serarslan, G | 1 |
| Araújo, EJ; Conchon-Costa, I; da Silva, SS; Fanti, JR; Felipe, I; Kawakami, NY; Miranda, MM; Mizokami, SS; Panis, C; Pavanelli, WR; Sforcin, JM; Teixeira, FH; Verri, WA; Watanabe, MA | 1 |
| Khamesipour, A; Mohammadi, AM; Nateghi Rostami, M; Seyyedan Jasbi, E | 1 |
| Ezatpour, B; Kheirandish, F; Mahmoudvand, H; Rashidipour, M; Saedi Dezaki, E; Sharifi, I | 1 |
| Abbas, O; Alam, E; Khalifeh, I; Moukarbel, R | 1 |
| Bertho, AL; Cunha, CF; Da-Cruz, AM; Ferraz, R; Lyra, MR; Pimentel, MI; Schubach, AO | 1 |
| Aït-Oudhia, K; Benbetka, S; Benikhlef, R; Eddaikra, N; Harrat, Z; Kherachi Djenad, I; Moulti-Mati, F; Oury, B; Sereno, D | 1 |
| Aristides, SM; Fernandes, AC; Lonardoni, MV; Pedroso, RB; Silveira, TG; Venazzi, EA; Zanzarini, PD | 1 |
| Hashemzadeh, S; Khoddami, M; Layegh, P; Rajabi, O | 1 |
| Azorin, D; Noguera-Morel, L; Xirotagaros, G | 1 |
| Aristides, SM; de Mello, TF; Demarchi, IG; Donatti, L; Fernandes, AC; Lonardoni, MV; Pedroso, RB; Silveira, TG; Venazzi, EA | 1 |
| Brasileiro, A; García-Martinez, P; Giménez-Arnau, AM; Martín-Ezquerra, G; Pujol, RM | 1 |
| Bedoya, A; Cruz-Barrera, ML; Daza, CD; Echeverry, MC; Lopez, MC; Mariño, ML; Perez-Franco, JE; Robayo, ML; Saavedra, CH | 1 |
| Andrade, MS; Corrêa-Júnior, JD; Demicheli, C; Fernandes, FR; Ferreira, LA; Frézard, F; Lanza, JS; Magalhães-Paniago, R; Melo, MN; Vilela, JM | 1 |
| Hajaliloo, E; Hajjaran, H; Kazemi-Rad, E; Khadem-Erfan, MB; Mohebali, M; Oshaghi, MA; Raoofian, R; Reisi Nafchi, H | 1 |
| Akhdari, N; Amal, S; Hocar, O; Ouadi, Z; Tassi, N | 1 |
| Cota, G; Rabello, A; Senna, MC; Silva, RE; Toledo, A | 1 |
| Arias-Santiago, S; Blasco-Morente, G; Martínez-López, A; Pérez-López, I | 1 |
| Corpas-López, V; Díaz-Sáez, V; Gijón-Robles, P; López-Viota, J; López-Viota, M; Martín-Sánchez, J; Merino-Espinosa, G; Morillas-Mancilla, MJ; Morillas-Márquez, F; Navarro Moll, MC | 1 |
| Barud, HS; Borges, VM; Celes, FS; de Oliveira, CI; Khouri, R; Ribeiro, SJ; Trovatti, E; Van Weyenbergh, J | 1 |
| Omidian, E; Radmanesh, M | 1 |
| Carvalho de Castro, E; de Araújo-Melo, MH; de Oliveira Schubach, A; de Vasconcellos Carvalhaes Oliveira, R; do Nascimento Brahim Paes, LR; Jardim Duarte, CC; Oliveira Bezerra, DC; Oliveira de Barcelos, R; Pereira Bom Braga, F; Ramos Ferreira Terceiro, B; Salgado de Sousa Torraca, T; Valete-Rosalino, CM | 1 |
| Handjani, F; Hatam, GR; Mohammadpour, I; Motazedian, MH | 1 |
| Caridha, D; Grogl, M; Harris, M; Hickman, M; Hudson, TH; Lang, T; Lecoeur, H; Leed, S; Ngundam, F; O'Neil, M; Parriot, S; Read, L; Sciotti, R; Sena, J | 1 |
| Marcoval, J; Penín, RM | 1 |
| Bonano, VI; Espada, CR; Miguel, DC; Reimão, JQ; Trinconi, CT; Uliana, SRB; Yokoyama-Yasunaka, JKU | 1 |
| Hussain, I; Janjua, SA; Munir, A | 1 |
| Galindo-Sevilla, N; Mancilla-Ramirez, J; Martinez-Rojano, H; Quiñonez-Diaz, L | 1 |
| Alborzi, A; Fakhar, M; Hatam, GR; Kadivar, MR; Motazedian, MH; Pouladfar, GR | 1 |
| Jaffary, F; Mahzoni, P; Nilforoushzadeh, MA; Sadeghian, G; Shirani-Bidabad, L; Ziaei, H | 1 |
| Achour Barchiche, N; Madiou, M | 1 |
| Coraspe, V; Delgado, O; Franco-Paredes, C; Navarro, P; Rivas, MA; Rodriguez-Morales, AJ; Silva, S | 1 |
| Amaral, VF; Canto-Cavalheiro, MM; Charret, KS; da Silva, EF; Echevarria, A; Leon, LL; Rodrigues, RF | 1 |
| Baron, AR; Dueñes, B; Mahecha, Mdel P; Montaña, R; Montero, LM; Reithinger, R; Sanchez, BF; Vega, JC | 1 |
| Badri, T; Ben Brahim, M; Ben Jannet, S; Chouk, S; Daghfous, R; El Aïdli, S; Fenniche, S; Marrrak, H; Mlika, BR; Mokhtar, I | 1 |
| Sadeghi, M; Sadeghian, G; Ziaei, H | 1 |
| Brito, ME; Luna, CF; Medeiros, AC; Pereira, VR; Reis, LC; Silva, CJ; Souza, MA | 1 |
| Layegh, P; Moghiman, T; Naviafar, P; Pezeshkpoor, F; Soruri, AH | 1 |
| Ansari, N; Firouz, A; Jaffary, F; Nilforoushan, Z; Nilforoushzadeh, MA; Siadat, AH | 1 |
| Mahmoudi, M; Nilforoushzadeh, MA; Saberi, S; Shirani-Bidabadi, L; Siadat, AH; Zolfaghari-Baghbaderani, A | 1 |
| Barral, AM; de Almeida, HL; Diehl, ES; Fleury, RN; Ura, S | 1 |
| Aitourhoui, M; Belgnaoui, FZ; Bouhllab, J; Elguelbazouri, N; Hassam, B; Marcil, T; Qasmi, S; Senouci, K | 1 |
| Akrout, R; Baklouti, S; Fourati, H; Hachicha, I; Hdiji, N; Sellami, M | 1 |
| Barnabas, GA; Morrone, A; Padovese, V; Terranova, M; Toma, L | 1 |
| Ejaz, A; Ul Bari, A | 1 |
| García-Lázaro, M; Natera, C; Rivero, A; Villar, C | 1 |
| Bacellar, O; Carvalho, EM; Guimarães, LH; Lago, EL; Machado, PR; Morgan, DJ; Schriefer, A | 1 |
| Firdous, R; Ranja, K; Yasinzai, M | 1 |
| Feily, A; Namazi, MR; Yaghoobi, R | 1 |
| Figueroa, RA; Miranda, MC; Prager, M; Zea, DF | 1 |
| Friedrich, K; Grimaldi, G; Marchevsky, RS; Miekeley, N; Paumgartten, FJ; Porrozzi, R; Teva, A; Vieira, F | 1 |
| Dorta, ML; Miguel, DC; Pelli de Oliveira, MA; Pereira, LI; Ribeiro-Dias, F; Uliana, SR; Yokoyama-Yasunaka, JK; Zauli-Nascimento, RC | 1 |
| Del Giudice, P; Dereure, J; Hakimi, S; Le Quellec, A; Rivière, S | 1 |
| Caldas, ED; Neves, DB; Sampaio, RN | 1 |
| Bagherani, N; Maraghi, S; Rafiei, A; Yaghoobi, R | 1 |
| Bianciardi, P; Cañavate, C; Cruz, I; Miró, G; Mortarino, M; Oliva, G; Vischer, C | 1 |
| Azeredo-Coutinho, RB; Baptista, C; Conceição-Silva, F; de Almeida Marzochi, MC; de Camargo Ferreira E Vasconcellos, E; de Fátima Madeira, M; de Matos Salgueiro, M; de Oliveira Schubach, A; de Souza Coutinho, R; Fernandes Pimentel, MI; Pereira Quintella, L; Roberto Mortari, S; Rosandiski Lyra, M; Soares Moreira, J; Valete-Rosalino, CM | 1 |
| Ezzine Sebai, N; Fazaa, B; Kamoun, MR; Khaled, A; Kharfi, M; Mrabet, N; Zeglaoui, F | 1 |
| Baba, M; Bal, N; Durdu, M; Eryilmaz, A; Yiğit, F | 1 |
| Adaui, V; Arévalo, J; Cupolillo, E; Dujardin, JC; Ribeiro-Alves, M; Romero, GA; Torres, DC | 1 |
| Aflatoonian, MR; Dowlati, Y; Fekri, AR; Khamesipour, A; Mahboudi, F; Modabber, F; Nadim, A; Sharifi, I | 1 |
| García, C; García, RG; Kampeerapappun, P; López, M; López-Jaramillo, P; Rincón, MY; Silva, SY; Smith, DJ; Smith, E; Vélez, ID | 1 |
| Ben Osman, A; Chaker, E; El Euch, D; Ishak, F; Kort, R; Mokni, M; Zaraa, I | 1 |
| Abbas, MM; Masood, S; Mumtaz, MJ; Rashid, BN; Tabassum, S; Ullah Rao, MS | 1 |
| Aghaie, H; Heshmatkhah, A; Shamsi Meymandi, S; Zandi, S | 1 |
| López, L; Mestra, L; Rodríguez, E; Rojas, C; Sánchez, X; Vélez, I | 1 |
| Alves, FP; Ashman, JA; Beckmann, AM; Bogatzki, LY; Campos-Neto, A; Coler, RN; Cowgill, KD; Fernandes, DF; Kahn, SJ; Nascimento, E; Piazza, FM; Pine, SO; Reed, SG; Vieira, EP | 1 |
| Guerra-Giraldez, C; Mortara, RA; Price, HP; Ramos, CS; Smith, DF; Uliana, SR; Yokoyama-Yasunaka, JK | 1 |
| Nilforoushzadeh, MA; Sadeghian, G; Shirani-Bidabadi, L; Ziaei, H | 1 |
| Arasteh, M; Babakoohi, S; Firooz, A; Kashani, MN; Nilforoushzadeh, MA; Sadr, B | 1 |
| Craft, N; Da-Cruz, AM; de Oliveira, MP; de Oliveira-Neto, MP; Maretti-Mira, AC; Pirmez, C | 1 |
| Achour, I; Chakroun, A; Charfeddine, I; Ghorbel, A; Hammami, B; Mnejja, M; Turki, H | 1 |
| Layegh, P; Rahsepar, AA; Rahsepar, S | 1 |
| Alcântara, L; Carvalho, EM; Glesby, MJ; Guimarães, LH; Machado, PR; Morgan, DJ; Newlove, T | 1 |
| Ayadi, N; Béji, M; Bouomrani, S; Farah, A | 1 |
| Habibi, S; Handjani, F; Hatam, GH; Motazedian, MH; Pourmohammadi, B; Sarkari, B | 1 |
| Dabiri, S; Javadi, A; Nadji, M; Shamsi Meymandi, M; Shamsi Meymandi, S | 1 |
| Delgado, G; Granados, D; Mariño, A; Plaza, D; Sánchez, Y | 1 |
| Costa, MA; da Veiga-Júnior, VF; de Souza Lima, MM; Dias-Filho, BP; dos Santos, AO; Nakamura, CV; Ueda-Nakamura, T | 1 |
| Cuzzi, T; de Camargo Ferreira e Vasconcellos, E; de Fátima Madeira, M; de Matos Salgueiro, M; de Oliveira Schubach, A; Lambert Passos, SR; Mouta-Confort, E; Quintella, LP; Valete-Rosalino, CM | 1 |
| Barati, M; Fasihi Harandi, M; Hakimi Parizi, M; Khamesipour, A; Nakhaee, N; Nosratabadi, J; Sharifi, I; Shokri, A | 1 |
| Amaral, V; Campos, MC; Canto-Cavalheiro, MM; Charret, KS; Dos Reis, C; Echevarria, A; Leon, LL; Rodrigues, RF | 1 |
| Harms, G; Reiter-Owona, I; Richter, J; Scherbaum, H; Stich, A | 1 |
| Friedrich, K; Grimaldi, G; Marchevsky, RS; Miekeley, N; Paumgartten, FJ; Porrozzi, R; Vieira, FA | 1 |
| de Souza, W; Godinho, JL; Rodrigues, JC; Silva, R; Simas-Rodrigues, C; Ürmenyi, TP | 1 |
| Garcerant, D; Gore Saravia, N; Miranda, MC; Montero, LM; Muvdi Arenas, S; Nicholls, RS; Osorio, L; Pérez, M; Prager, M; Rodríguez-Barraquer, I; Rojas, MX; Rubiano, LC | 1 |
| Alvi, RU; Masood, S; Naveed, S | 1 |
| Abebe, Z; Dassoni, F; Morrone, A; Naafs, B | 1 |
| Case, AJ; Davis, GD; Hamid, H; Nadir, M; Robert, LL; Safi, N | 1 |
| Assareh, A; Azarian, B; Hadighi, R; Hajjaran, H; Mohebali, M; Vaziri, B | 1 |
| López, L; Robayo, M; Vargas, M; Vélez, ID | 1 |
| Andrade, LC; Daher, EF; Junior, GB; Libório, AB; Lima, CG; Martins, AM; Mota, RM; Oliveira, RA; Sanches, TR; Seguro, AC | 1 |
| Azeredo-Coutinho, RB; Baptista, C; de Oliveira, Rde V; Madeira, Mde F; Moreira, JS; Pimentel, MI; Salgueiro, Mde M; Schubach, Ade O; Silva, Fda C; Valete-Rosalino, CM; Vasconcellos, Ede C | 1 |
| de Saldanha, RR; Martins-Papa, MC; Muniz-Junqueira, MI; Sampaio, RN | 1 |
| Esfandiarpour, I; Farajzadeh, S; Fathabadi, EA; Heshmatkhah, A; Rahnama, Z | 1 |
| Aguado-Lobo, M; Borbujo, J; Espinosa-Lara, P; García-Donoso, C; Martínez-Sánchez, D; Moreno-Torres, A; Romero-Maté, A; Tardío, JC | 1 |
| Aguado, M; Borbujo, J; Córdoba, S; Gandolfo Cano, M; Huerta-Brogera, M; Martínez-Morán, C; Romero, A | 1 |
| Dastgheib, L; Mirashe, Z; Naseri, M | 1 |
| Duffey, GB; Horton, LE; Paniz Mondolfi, AE; Perez-Alvarez, A; Reyes Jaimes, O; Tirado, M; Zerpa, O | 1 |
| Brelaz-de-Castro, MC; da Rocha, LF; de Almeida, AF; de Assis-Souza, M; de Oliveira, AP; Pereira, VR | 1 |
| Molinet, FJ; Noronha, EF; Romero, GA | 1 |
| Alchorne, MM; Macedo, FS; Ogawa, MM; Tomimori-Yamashita, J | 1 |
| Aminjavaheri, M; Momeni, AZ; Reiszadae, MR | 1 |
| Alavi, A; Esfandiarpour, I | 1 |
| Handjani, F; Nouhpisheh, MK; Salmanpour, R | 1 |
| Bulut, V; Gur, S; Gurel, MS; Kocyigit, A; Ulukanligil, M | 1 |
| Abolhassani, M; Alimohammadian, MH; Darabi, H; Kariminia, A | 1 |
| Belhadj, S; Chaker, E; Dedet, JP; Hammami, M; Kallel, K; Pratlong, F | 1 |
| Faghihi, G; Tavakoli-kia, R | 1 |
| Gianotti, R; Rigoni, C; Veraldi, S | 1 |
| Badaró, R; Bittencourt, A; Follador, I; Nunes, VL; Silva, N; Straatmann, A | 1 |
| Báfica, A; Barral, A; Freitas, LA; Nascimento, EG; Oliveira, F | 1 |
| Bogenrieder, T; Landthaler, M; Lehn, N; Stolz, W | 1 |
| Flores M, RM; Macêdo, Vde O; Noronha, EF; Romero, GA | 1 |
| Enk, CD; Gardlo, K; Hochberg, M; Ingber, A; Ruzicka, T | 1 |
| Bhutto, AM; Hashiguchi, Y; Nonaka, S; Soomro, RA | 1 |
| Cordova, X; Sorci, JJ; Usatine, RP | 1 |
| Barão, SC; Giorgio, S | 1 |
| Amini Harandi, A; Asilian, A; Faghihi, G; Momeni, A; Sadeghinia, A | 1 |
| FLOCH, H | 1 |
| Bari, I; Ejaz, A; Iftikhar, N | 1 |
| Darie, H; Debord, T; Gros, P; Imbert, P; Rapp, C; Roué, R; Simon, F | 1 |
| da Silva, JB; de Melo, AL; Demicheli, C; Falcão, CA; Frézard, F; Ochoa, R; Rossi-Bergmann, B; Sinisterra, RD | 1 |
| ESCHER, D; LAHAM, E | 1 |
| CORNEJO, A | 1 |
| Cardenas, GA; Cohen, C; Gonzalez-Serva, A | 1 |
| Isaac-Márquez, AP; Lezama-Dávila, CM | 1 |
| Lamothe, J | 1 |
| Asilian, A; Faghihi, G; Momeni, A; Sadeghinia, A | 1 |
| Armijos, RX; Calvopiña, M; Mancheno, M; Rodriguez, R; Weigel, MM | 1 |
| Asilian, A; Iraji, F; Momeni, AZ; Shahtalebi, MA; Vali, A | 1 |
| Allahverdiyev, AM; Culha, G; Durdu, M; Memisoglu, HR; Uzun, S | 1 |
| Querido, J | 1 |
| Asilian, A; Enshaeieh, Sh; Faghihi, G; Shariati, F; Sharif, A; Siadat, AH | 1 |
| de Carvalho, EM; de Farias Guerra, MV; de la Glória Orge Orge, M; de Oliveira Macêdo, V; Paes, MG; Romero, GA | 1 |
| Cardoso, JE; de Oliveira-Silva, F; Fernandes, AP; Ferreira, LA; Gonçalves, GS; Maciel, FC; Rabello, A; Souza, RC | 1 |
| Gómez, A; Henao, HH; Osorio, Y; Saravia, NG; Travi, B | 1 |
| Bouassida, S; Boudaya, S; Maalej, N; Masmoudi, A; Mseddi, M; Souissi, A; Turki, H; Zahaf, A | 1 |
| Andersen, EM; Berman, JD; Colina, O; Cruz-Saldarriaga, M; Echevarria, J; Llanos-Cuentas, A; Luz-Cjuno, M; Miranda-Verastegui, C | 1 |
| Barral, A; Boaventura, V; Campos, LF; Costa, JM; da Cruz Junior, AC; da Rocha, AV; de Oliveira, CI; Noronha, A; Novais, FO; Oliveira, JG | 1 |
| Serarslan, G; Söğüt, S; Yilmaz, HR | 1 |
| Cruz, I; Flores, MD; López-Vélez, R; Mateo, M | 1 |
| Berman, J; Soto, J; Toledo, J; Vega, J | 1 |
| Arévalo, I; Llanos-Cuentas, A; Matlashewski, G; Miranda-Verástegui, C; Ward, BJ | 1 |
| Guarneri, C; Guarneri, F | 1 |
| Badaro, R; Correia, TM; David, JR; de Freitas, LA; Lobo, IM; Nakatani, M; Netto, E; Oliveira, MI; Soares, MB | 1 |
| Moosavi, Z; Nakhli, A; Rassaii, S | 1 |
| Bouassida, S; Kitar, A; Masmoudi, A; Rebai, M; Turki, H; Zahaf, A | 1 |
| Cavalli, R; Cremonesi, R; Galloni, C; Veraldi, S | 1 |
| Atabek, ME; Pirgon, O; Unal, E | 1 |
| Aşçioglu, O; Canoz, O; Doganay, M; Ferahbaş, A; Mistik, S; Utaş, S; Yaman, O | 1 |
| Boudaya, S; Maalej, N; Masmoudi, A; Turki, H; Zahaf, A | 1 |
| Boucher, P; Hadighi, R; Hajjaran, H; Khamesipour, A; Mohebali, M; Ouellette, M | 1 |
| Ouellette, M; Rojas, R; Saravia, NG; Valderrama, L; Valderrama, M; Varona, MX | 1 |
| Boumis, E; Chinello, P; Della Rocca, C; Paglia, MG; Petrosillo, N; Proietti, MF | 1 |
| Katsambas, A; Kontochristopoulos, G; Papakonstantinou, AM; Petropoulou, H; Stavropoulos, PG | 1 |
| Nilforoushzadeh, MA; Sadeghian, G | 1 |
| Buffet, PA; Darie, H; Freitag, S; Gounod, N; Le Guern, AS; Therby, A; Van Der Vliet, D | 1 |
| Ansari, N; Jaffray, F; Nilfrousihzadeh, MA; Reiszadeh, MR | 1 |
| Abtahi, N; Razmavar, MR; Salmanpour, R | 1 |
| Bermúdez, H; Boelaert, M; Chappuis, F; Desjeux, P; Dujardin, JC; Garcia, L; Rojas, E | 1 |
| Grimaldi, GJ; Oliveira-Neto, MP; Porrozzi, R; Teva, A | 1 |
| Costa, M; Ferrer, L; Martorell, S; Miranda, S; Ramis, A | 1 |
| Shajari, G; Taghaviardakani, A; Talaei, R; Talari, SA; Vakili, Z | 1 |
| Dowlati, Y; Eskandari, SE; Firooz, A; Ghoorchi, MH; Gorouhi, F; Hooshmand, B; Khamesipour, A; Khatami, A; Nassiri-Kashani, M; Rashighi-Firoozabadi, M | 1 |
| Cruz, A; Herwaldt, BL; Palacios, R; Rainey, PM; Saravia, NG; Stagni, G; Trujillo, R | 1 |
| Cadena, H; Tabares, CJ; Travi, BL | 1 |
| Mumtaz, N; Rahman, SB; ul Bari, A | 1 |
| Iraji, F; Nilfroushzadeh, MA; Sadeghian, G | 1 |
| Barroso, PA; Calvopina, M; Hashiguchi, Y; Kato, H; Korenaga, M; Marco, JD | 1 |
| Derakhshan, R; Haftbaradaran, E; Jaffary, F; Moradi, S; Nilforoushzadeh, MA | 1 |
| Adaui, V; Arevalo, J; Chappuis, F; De Doncker, S; Dujardin, JC; Lazo, M; Llanos-Cuentas, A; Loayza-Muro, R; Maurer, A; Miranda-Verástegui, C; Ramirez, L; Tulliano, G; Zimic, M | 1 |
| Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Pollack, H; Quispe, A; Spaeth, G; Tulliano, G | 1 |
| Fontes, CJ; Hueb, M; Nery, AF; Rodrigues, AM | 1 |
| Frutuoso, MS; Pompeu, MM; Silva, TM; Sólon, FR; Sousa, AQ; Teixeira, MJ | 1 |
| Aguado, JM; Costa, JR; López-Medrano, F; Rodriguez-Peralto, JL | 1 |
| Akhoundi, B; Fotouhi, A; Hooshmand, B; Kabir, MJ; Mohebali, M; Nadim, A; Rahnema, A; Razaghian, AR; Zarei, Z | 1 |
| Boucher, P; Hadighi, R; Khamesipour, A; Meamar, AR; Mohebali, M; Ouellette, M; Roy, G | 1 |
| Dabiri, SH; Esfandiarpour, I; Yousefi, K | 1 |
| Layegh, P; Moghiman, T; Pezeshkpoor, F; Shakeri, MT; Vosugh, EM; Yazdanpanah, MJ | 1 |
| Azeredo-Coutinho, RB; Callahan, H; Max, G; Mendonça, SC; Portal, AC | 1 |
| Dabiri, SH; Esfandiarpour, I | 1 |
| Bottini, S; Lunardon, L; Persico, MC; Veraldi, S | 1 |
| Akrout, F; Ayadi, N; Bouassida, S; Boudaya, S; Khabir, A; Masmoudi, A; Meziou, TJ; Sallemi, T; Turki, H; Zahaf, A | 1 |
| Abraham, D; Cajal, SP; Juarez, M; Krolewiecki, AJ; Matsumoto, T; Mimori, T; Romero, HD; Taranto, NJ | 1 |
| Amaral, FM; Aragão-Filho, WC; Costa, GC; Frazão, JB; Guerra, RN; Maciel, MC; Nascimento, FR; Patrício, FJ; Pereira, PV; Pereira, WS; Rebêlo, JM; Ribeiro, MN; Silva, LA; Sousa, SM | 1 |
| Amato Neto, V; Amato, VS; Graf, ME; Nicodemo, AC; Siqueira, AM; Tuon, FF | 1 |
| Dahdah, MJ; Ghosn, S; Kibbi, AG | 1 |
| Balderrama, M; Berman, JD; Rea, J; Soto, J; Soto, P; Toledo, J; Valda, L | 1 |
| Akkaya, VB; Basak, PY; Ceyhan, AM; Erturan, I; Yildirim, M | 1 |
| Akrout, F; Ayadi, N; Bouassida, S; Boudawara, T; Bouzid, L; Khabir, A; Masmoudi, A; Meziou, TJ; Turki, H; Zahaf, A | 1 |
| Elfekih, N; Ezzine, N; Fazaa, B; Hajlaoui, K; Kamoun, MR; Kastalli, S; Loueslati, MH; Zeglaoui, F | 1 |
| Buffet, P; Caumes, E; Gentilini, M | 1 |
| Berman, J; Grogl, M; Hernandez, N; Mejia, H; Soto, J | 1 |
| Hernández, DE; Martínez, C; Oliver, M; Planas, G | 1 |
| Aminjavaheri, M; Momeni, AZ | 2 |
| Aragort de Rossell, R; de Jesús de Durán, R; Rodríguez, AM; Rossell, O | 1 |
| Furtado, T; Nogueira-Castañon, MC; Pereira, CA | 1 |
| Barroeta, S; Bonfante-Garrido, R; de Alejos, MA; Grimaldi Júnior, G; Meléndez, E; Momen, H; Torrealba, J; Valdivia, O | 1 |
| Ferreira, ME; Fournet, A; Fuentes, S; Hocquemiller, R; Nakayama, H; Rojas De Arias, A; Schinini, A; Torres De Ortiz, S | 1 |
| Bertho, AL; Coutinho, SG; Da-Cruz, AM; De Luca, PM; McMahon-Pratt, D; Mendonça, SC; Oliveira, MP; Soong, L | 1 |
| Bai, M; Kastanioudakis, I; Kostoula, A; Skevas, A | 1 |
| Agudelo, S; Berman, J; Grogl, M; Hendrickx, E; Modabber, F; Puerta, J; Velez, I | 1 |
| Bouthelier Moreno, M; de Juan Martín, F; Fortuño Cebamanos, B; Gilaberte Calzada, Y; Justa Roldán, ML; Navarro Serrano, E; Sáez de Adana Pérez, E | 1 |
| Gonçalves-Costa, SC; Mattos, M; Oliveira-Neto, MP; Pirmez, C; Schubach, A | 2 |
| Alvarez, E; Canales, J; Davies, CR; Dye, C; Leon, E; Llanos-Cuentas, EA; Roncal, N; Sharp, SJ | 1 |
| Isaza, DM; Mosca, W; Restrepo, M | 1 |
| Berman, J; Fuya, P; Herrera, R; Soto, J | 1 |
| Black, GF; Blackwell, JM; Braga, R; Ishikawa, EA; Kima, P; McMahon-Pratt, D; Quinnell, RJ; Shaw, JJ; Shaw, MA; Silveira, FT; Soong, L | 1 |
| Abahussein, A; al-Gindan, Y; Alkhawajah, AM; Jain, S; Larbi, E | 1 |
| Aste, N; Biggio, P; Ferreli, C; Pau, M | 1 |
| Aktepe, N; Avci, S; Erel, O; Gurel, MS; Kocyigit, A; Seyrek, A; Vural, H | 1 |
| Abajo, P; Daudén, E; Martín, R | 1 |
| Gilead, L; Horev, L; Jonas, F; Klaus, SN; Zlotogorski, A | 1 |
| Fernandes, O; Mattos, M; Oliveira-Neto, MP; Pirmez, C; Souza, CS | 1 |
| Robledo, SM; Saravia, NG; Valencia, AZ | 1 |
| Krause, G; Kroeger, A | 1 |
| Khalid, M; Mujtaba, G | 1 |
| Ardehali, S; Handjani, F; Panjehshahin, MR; Salmanpour, R; Tabatabaee, HR; Tabei, SZ; Zerehsaz, F | 1 |
| Greiner, M; Moritz, A; Steuber, S | 1 |
| Greiner, M; Moritz, A; Schirrmann, I; Steuber, S | 1 |
| Blackwell, JM; Cabrera, M; Castes, M; Convit, J; Shaw, MA; Trujillo, D | 1 |
| Andrade-Narvaez, FJ; Canto-Lara, SB; Damian-Centeno, AG; Vargas-Gonzalez, A | 1 |
| Barreto, SM; Krettli, AU; Lima e Costa, MF; Passos, VM; Romanha, AJ; Volpini, AC | 1 |
| Hepburn, NC | 1 |
| Ahmadiani, A; Azar, A; Ebtekar, M; Ghazanfari, T; Hassan, ZM; Naderi, G | 1 |
| Banzet, S | 1 |
| Afonso, LC; Costa , CA; Genaro, O; Gollob, KJ; Mayrink, W; Oliveira, MA; Pinto, JA; Toledo, VP | 1 |
| Añez, N; Cazorla, D; Sánchez de Mirt, A; Yépez, J | 1 |
| Develoux, M; Huerre, M; Ndiaye, B; Thierno, DM | 1 |
| Dordain, ML; Rapp, C; Simon, F | 1 |
| Alvarez, E; Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Meng, TC; Miller, R; Najar, E; Ward, B | 1 |
| Guerra, MV; Macêdo, VO; Paes, MG; Romero, GA | 1 |
| Arana, B; Diaz, A; Rizzo, N | 1 |
| Armijos, RX; Weigel, MM | 1 |
| Añez, N; Gonzalez, N; Guevara, P; Premoli-de-Percoco, G; Ramirez, JL | 1 |
| De Souza, AA; Ishikawa, EA; Lainson, R; Silveira, FT | 1 |
| da Costa, CA; Genaro, O; Machado-Pinto, J; Marques, MJ; Mayrink, W; Modabber, F; Pinto, J | 1 |
| Benjelloune, A; Berraho, A; Charif Chefchaouni, M; El Lyacoubi, M; Lamrani, R | 1 |
| Calza, L; Chiodo, F; di Bari, MA; Manfredi, R | 1 |
| Barrios, AA; Cavé, A; Fournet, A; Hocquemiller, R; Muñoz, V | 1 |
| Franke, ED; Grogl, M; Thomason, TN | 1 |
| Bigaignon, G; Cornu, G; Mattot, M; Ninane, J; Vermylen, C | 1 |
| da Costa, CA; Dias, M; Genaro, O; Lima, Ade O; Magalhaes, PA; Mayrink, W; Melo, MN; Michalick, MS; Nascimento, E; Toledo, VP | 1 |
| Anastassiadis, G; Asvesti, C; Kolokotronis, A; Zographakis, I | 1 |
| Berman, JD; Herwaldt, BL; Neva, FA | 1 |
| Marr, JJ; Martinez, S | 1 |
18 review(s) available for meglumine antimoniate and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Global distribution of treatment resistance gene markers for leishmaniasis.
Topics: Antimony Sodium Gluconate; Antiprotozoal Agents; Biomarkers; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2022 |
Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
Topics: Administration, Topical; Adult; Antiprotozoal Agents; Brazil; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Injections, Intravenous; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Middle Aged; Young Adult | 2019 |
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hyperthermia, Induced; Immunocompetence; Injections, Intramuscular; Injections, Intravenous; Interferon-gamma; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Pentoxifylline; Phosphorylcholine; Randomized Controlled Trials as Topic | 2020 |
Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
Topics: Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Cryotherapy; Databases, Factual; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2017 |
The successful use of radiofrequency-induced heat therapy for cutaneous leishmaniasis: a review.
Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Child; Child, Preschool; Cytokines; Female; Hot Temperature; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Pentostatin; Radiofrequency Therapy; Young Adult | 2018 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis.
Topics: Antiprotozoal Agents; Drug Hypersensitivity Syndrome; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Multiple Organ Failure | 2018 |
Interventions to treat cutaneous leishmaniasis in children: A systematic review.
Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Phosphorylcholine; Rifampin | 2018 |
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Patents as Topic; Phosphorylcholine | 2019 |
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis.
Topics: Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Non-Randomized Controlled Trials as Topic; Phosphorylcholine; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Cutaneous leishmaniasis in North Africa: a review.
Topics: Africa, Northern; Animals; Antiprotozoal Agents; Climate; Disease Outbreaks; Disease Reservoirs; Endemic Diseases; Humans; Incidence; Insect Vectors; Leishmania infantum; Leishmania major; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus; Rodentia; Virulence; Zoonoses | 2014 |
Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.
Topics: Confidence Intervals; Controlled Clinical Trials as Topic; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Models, Biological; Organometallic Compounds; Treatment Outcome | 2015 |
Cutaneous Leishmaniasis of the Eyelids: A Case Series with Molecular Identification and Literature Review.
Topics: Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Cytological Techniques; Eyelid Diseases; Eyelids; Female; Humans; Infant; Injections, Intramuscular; Iran; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Microbiological Techniques; Microscopy; Organometallic Compounds; Phylogeny; Polymerase Chain Reaction; Sequence Analysis, DNA | 2016 |
Intermediate/borderline disseminated cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Child; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2013 |
[Cutaneous leishmaniasis].
Topics: Amphotericin B; Anti-Bacterial Agents; Antimony Sodium Gluconate; Antiprotozoal Agents; Controlled Clinical Trials as Topic; Diagnosis, Differential; Double-Blind Method; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Photochemotherapy; Time Factors | 2003 |
Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Developing Countries; Endemic Diseases; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Pentamidine | 2008 |
[Treatment of localized cutaneous leishmaniasis].
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Itraconazole; Ketoconazole; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentamidine | 1994 |
Cutaneous leishmaniasis.
Topics: Amphotericin B; Animals; Antifungal Agents; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Life Cycle Stages; Macrophages; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prevalence; Skin | 2000 |
Chemotherapy of cutaneous leishmaniasis: a review.
Topics: Antifungal Agents; Antimony; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Ointments; Organometallic Compounds; Phosphorylcholine | 2001 |
73 trial(s) available for meglumine antimoniate and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Brazil; Female; Follow-Up Studies; Humans; Injections, Intralesional; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.
Topics: Adult; Antiprotozoal Agents; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Outcome | 2022 |
Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
Topics: Antiprotozoal Agents; Humans; Injections, Intramuscular; Iran; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2022 |
Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Female; Humans; Iran; Leishmania major; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pilot Projects; Treatment Outcome | 2022 |
Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
Topics: Animals; Antiprotozoal Agents; Dogs; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Saline Solution; Ulcer | 2023 |
A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2023 |
Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Drug Hypersensitivity; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Risk | 2020 |
Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial.
Topics: Acute Disease; Adult; Antiprotozoal Agents; Case-Control Studies; Female; Humans; Injections, Intralesional; Intense Pulsed Light Therapy; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Treatment Outcome | 2021 |
Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran.
Topics: Adolescent; Adult; Antiprotozoal Agents; Caustics; Drug Therapy, Combination; Female; Humans; Iran; Leishmaniasis, Cutaneous; Logistic Models; Male; Meglumine Antimoniate; Middle Aged; Treatment Outcome; Trichloroacetic Acid; Young Adult | 2020 |
Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leishmaniasis, Cutaneous; Macrophage Colony-Stimulating Factor; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.
Topics: Brazil; Dose-Response Relationship, Drug; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2017 |
Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Brazil; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome; Young Adult | 2018 |
Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis.
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Cyclopropanes; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Pilot Projects; Treatment Outcome; Young Adult | 2021 |
Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
Topics: Adolescent; Adult; Antiprotozoal Agents; Bandages; Child; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Young Adult | 2013 |
A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Cimetidine; Double-Blind Method; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome; Young Adult | 2015 |
Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
Topics: Acute Disease; Administration, Cutaneous; Adolescent; Adult; Antiprotozoal Agents; Azithromycin; Child; Drug Administration Schedule; Female; Humans; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Liposomes; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Time Factors; Treatment Outcome; Young Adult | 2016 |
Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
Topics: Adolescent; Adult; Female; Humans; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome | 2008 |
Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Topics: Antiprotozoal Agents; Child; Child, Preschool; Cryotherapy; Female; Humans; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2009 |
A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Antiprotozoal Agents; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Omeprazole; Organometallic Compounds; Treatment Outcome; Young Adult | 2008 |
Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Endemic Diseases; Humans; Insect Bites and Stings; Leishmania major; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Pakistan; Psychodidae; Young Adult | 2009 |
Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2009 |
A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.
Topics: Administration, Topical; Adolescent; Adult; Colombia; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Nitric Oxide; Organometallic Compounds; Treatment Outcome; Young Adult | 2010 |
Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Combined Modality Therapy; Cryotherapy; Female; Follow-Up Studies; Humans; Injections, Intralesional; Laser Therapy; Lasers, Gas; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Time Factors; Treatment Outcome; Young Adult | 2011 |
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Capsules; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Phosphorylcholine; Young Adult | 2010 |
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antibodies, Protozoan; Antibody Formation; Antigens, Protozoan; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Polyproteins; Protozoan Vaccines; Recombinant Proteins; Young Adult | 2010 |
Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun.
Topics: Acute Disease; Adolescent; Adult; Child; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesotherapy; Organometallic Compounds; Pain; Treatment Outcome; Young Adult | 2010 |
Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Cutaneous; Male; Medication Adherence; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Young Adult | 2011 |
Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis.
Topics: Adolescent; Adult; Anthelmintics; Antiprotozoal Agents; Double-Blind Method; Drug Therapy, Combination; Female; Helminthiasis; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Young Adult | 2011 |
Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
Topics: Administration, Oral; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Treatment Failure | 2012 |
Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Aged; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Hyperthermia, Induced; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
Topics: Adult; Aged; Antiprotozoal Agents; Chi-Square Distribution; Colombia; Drug Administration Schedule; Female; Health Facilities; Humans; Hyperthermia, Induced; Injections, Intramuscular; Kaplan-Meier Estimate; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Military Facilities; Organometallic Compounds; Recurrence; Time Factors; Treatment Outcome | 2012 |
Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial.
Topics: Administration, Oral; Adult; Allopurinol; Anti-Bacterial Agents; Antimetabolites; Antiprotozoal Agents; Azithromycin; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2012 |
Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
Topics: Adolescent; Adult; Allopurinol; Antimetabolites; Antiprotozoal Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2002 |
Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Adolescent; Allopurinol; Antiprotozoal Agents; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2002 |
Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Injections, Intralesional; Ketoconazole; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2001 |
Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antimony; Antiprotozoal Agents; Child; Cytokines; Humans; Inflammation; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2002 |
Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Topics: Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Paromomycin; Treatment Outcome | 2003 |
Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Combined Modality Therapy; Cryotherapy; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2004 |
Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Topics: Administration, Topical; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzethonium; Double-Blind Method; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Treatment Failure; Urea | 2004 |
Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis.
Topics: Acute Disease; Adolescent; Adult; Aged; Antiprotozoal Agents; Case-Control Studies; Child; Child, Preschool; Double-Blind Method; Female; Humans; Injections, Intralesional; Injections, Subcutaneous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome; Zinc Sulfate | 2004 |
Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Carbon Dioxide; Child; Female; Humans; Laser Therapy; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2004 |
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Female; Humans; Infusions, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentamidine; Peru; Treatment Outcome | 2005 |
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
Topics: Adjuvants, Immunologic; Administration, Topical; Adolescent; Adult; Aged; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Peru | 2005 |
Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Cytokines; Female; Hot Temperature; Humans; Interferon-gamma; Interleukin-10; Interleukin-5; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; Injections, Intralesional; Leishmania major; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Ointments; Organometallic Compounds; Paromomycin; Treatment Outcome | 2005 |
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.
Topics: Adult; Animals; Antiprotozoal Agents; Drug Resistance; Female; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2006 |
Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentoxifylline; Treatment Outcome | 2006 |
Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Combined Modality Therapy; Cryotherapy; Humans; Injections, Intralesional; Iran; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2006 |
Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Leishmaniasis, Cutaneous; Lymphocyte Subsets; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors | 2007 |
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Animals; Antimony; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Single-Blind Method; Treatment Outcome | 2006 |
Miltefosine in cutaneous leishmaniasis.
Topics: Adult; Antimony; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2007 |
Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.
Topics: Adolescent; Adult; Antiprotozoal Agents; Female; Hot Temperature; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Radiofrequency Therapy | 2007 |
Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Drug Therapy, Combination; Honey; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prospective Studies; Treatment Outcome | 2007 |
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Animals; Antiprotozoal Agents; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Imiquimod; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pilot Projects; Treatment Outcome | 2007 |
Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Female; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine; Zoonoses | 2007 |
Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2007 |
A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Adult; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Argentina; Azithromycin; Endemic Diseases; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2007 |
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Bolivia; Child; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Time Factors; Treatment Outcome | 2008 |
Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Topics: Administration, Topical; Adolescent; Adult; Animals; Antiprotozoal Agents; Benzethonium; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections, Intramuscular; Injections, Intravenous; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Paromomycin | 1995 |
Treatment of recurrent cutaneous Leishmaniasis.
Topics: Adolescent; Adult; Aged; Allopurinol; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Recurrence; Treatment Outcome | 1995 |
Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
Topics: Adult; Allopurinol; Antimetabolites; Antimony; Antiprotozoal Agents; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Failure | 1997 |
Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens.
Topics: Adult; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1997 |
A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
Topics: Adolescent; Adult; Age Factors; Animals; Antiprotozoal Agents; Brazil; Child; Female; Follow-Up Studies; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Mucous Membrane; Organometallic Compounds; Recurrence; Treatment Failure | 1997 |
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Topics: Antiprotozoal Agents; Benzethonium; Double-Blind Method; Drug Therapy, Combination; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin | 1998 |
Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration.
Topics: Adolescent; Adult; Antiprotozoal Agents; Female; Humans; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 1997 |
Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 1999 |
A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Infant; Injections, Intramuscular; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Plant Extracts; Treatment Outcome | 1999 |
Clinical follow-up examination after treatment of canine leishmaniasis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Follow-Up Studies; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 1998 |
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2001 |
Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunotherapy, Active; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2002 |
Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil.
Topics: Adolescent; Adult; Aged; Animals; Brazil; Child; Child, Preschool; Female; Humans; Immunotherapy, Active; Leishmania; Leishmania guyanensis; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Protozoan Vaccines | 1992 |
Allopurinol in the treatment of American cutaneous leishmaniasis.
Topics: Allopurinol; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1992 |
Allopurinol in the treatment of American cutaneous leishmaniasis.
Topics: Adolescent; Adult; Allopurinol; Antimony; Antiprotozoal Agents; Child, Preschool; Developing Countries; Drug Synergism; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1992 |
308 other study(ies) available for meglumine antimoniate and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
ASSESSMENT OF THE OXIDATIVE AND NITROSATIVE STRESS IN THE SERUM OF SAUDI PATIENTS WITH CUTANEOUS LEISHMANIASIS BEFORE AND AFTER TREATMENT.
Topics: Antimony Sodium Gluconate; Antiprotozoal Agents; Case-Control Studies; Humans; Leishmaniasis, Cutaneous; Macrophages; Male; Meglumine Antimoniate; Nitrosative Stress; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species | 2021 |
Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
Topics: Antiprotozoal Agents; Humans; Injections, Intralesional; Leishmania infantum; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spain; Treatment Outcome | 2022 |
Antiproliferative properties of Turmerone on Leishmania major: Modes of action confirmed by antioxidative and immunomodulatory roles.
Topics: Animals; Antioxidants; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Molecular Docking Simulation; Organometallic Compounds | 2022 |
Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis.
Topics: Antiprotozoal Agents; Bolivia; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Meglumine Antimoniate; Treatment Outcome | 2022 |
Eugenol derivatives with 1,2,3-triazole moieties: Oral treatment of cutaneous leishmaniasis and a quantitative structure-activity relationship model for their leishmanicidal activity.
Topics: Animals; Antiprotozoal Agents; Eugenol; Female; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Quantitative Structure-Activity Relationship; Structure-Activity Relationship; Triazoles | 2022 |
Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions.
Topics: Animals; Antiprotozoal Agents; Diptera; Larva; Leishmania major; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Wound Healing | 2022 |
[Generalized old world leishmaniasis: first Moroccan case in an immunocompetent adult?]
Topics: Adult; Amphotericin B; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine Antimoniate | 2021 |
Systemic meglumine antimoniate-induced severe dilated cardiomyopathy.
Topics: Antiprotozoal Agents; Cardiomyopathy, Dilated; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2022 |
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Reproducibility of Results; Retrospective Studies; Treatment Outcome | 2022 |
"It's not all about the disease": do treatment and socioeconomic status affect perceived impact and satisfaction of patients treated for cutaneous leishmaniasis?
Topics: Antiprotozoal Agents; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Patient Satisfaction; Social Class | 2023 |
Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-α inhibitors.
Topics: Antiprotozoal Agents; Humans; Immunologic Factors; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Meglumine Antimoniate; Retrospective Studies; Tumor Necrosis Factor Inhibitors | 2023 |
Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran.
Topics: Allopurinol; Antiprotozoal Agents; Humans; Iran; Itraconazole; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2023 |
Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2023 |
Naloxone Effects Against Cutaneous Leishmaniasis Caused by
Topics: Animals; Antiprotozoal Agents; Leishmania major; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Skin | 2023 |
A Novel Topical Formulation of the Leishmaniasis Drug Glucantime as a Nanostructured Lipid Carrier-Based Hydrogel.
Topics: Animals; Antiprotozoal Agents; Drug Carriers; Female; Hydrogels; Leishmaniasis, Cutaneous; Lipids; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Parasites | 2023 |
Antileishmanial, cellular mechanisms, and cytotoxic effects of green synthesized zinc nanoparticles alone and in combined with glucantime against Leishmania major infection.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Caspase 3; Leishmania major; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Zinc | 2023 |
Comparative analysis of the severity and progression of cutaneous leishmaniasis caused by Leishmania tropica in untreated and glucantime-treated patients.
Topics: Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2023 |
The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Epoxy Compounds; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred BALB C | 2019 |
Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Topics: Adiponectin; Amiodarone; Animals; Anti-Arrhythmia Agents; Antiprotozoal Agents; Cell Line; Female; Glutathione Peroxidase; Inhibitory Concentration 50; Interleukin-6; Leishmania major; Leishmaniasis, Cutaneous; Lymph Nodes; Macrophages; Malondialdehyde; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Parasite Load; Random Allocation; Skin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2019 |
[Cutaneous leishmaniasis of the vermilion border of the upper lip extending to the oral mucosa].
Topics: Adolescent; Facial Dermatoses; Female; Fluconazole; Humans; Leishmaniasis, Cutaneous; Lip; Lip Diseases; Meglumine Antimoniate; Morocco; Mouth Mucosa | 2020 |
"Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia.
Topics: Antimony Sodium Gluconate; Antiprotozoal Agents; Bolivia; Budgets; Cost Savings; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2019 |
Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cytokines; Female; Humans; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Lymph Nodes; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Parasite Load; Random Allocation; Sirolimus; TOR Serine-Threonine Kinases | 2019 |
Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Amphotericin B; Child; Child, Preschool; Female; Humans; Immunocompromised Host; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Middle Aged; Retrospective Studies; Risk Factors; Spain; Young Adult | 2020 |
Clinical Presentation and Response to Therapy in Children with Cutaneous Leishmaniasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged | 2020 |
American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.
Topics: Amphotericin B; Antiprotozoal Agents; French Guiana; Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Retrospective Studies; United States | 2020 |
Sugar-based colloidal nanocarriers for topical meglumine antimoniate application to cutaneous leishmaniasis treatment: Ex vivo cutaneous retention and in vivo evaluation.
Topics: Administration, Cutaneous; Administration, Topical; Animals; Antiprotozoal Agents; Colloids; Drug Carriers; Female; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Models, Animal; Nanoparticles; Particle Size; Polysaccharides; Skin; Sugars; Swine; Treatment Outcome | 2020 |
Relationship of Leishmania RNA Virus (LRV) and treatment failure in clinical isolates of Leishmania major.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniavirus; Male; Meglumine Antimoniate; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA, Viral; Sequence Analysis, DNA; Treatment Failure | 2020 |
Comparison of
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Female; Genotyping Techniques; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Real-Time Polymerase Chain Reaction; Turkey | 2020 |
Cutaneous leishmaniasis of the face treated with imiquimod 3.75.
Topics: Humans; Imiquimod; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2021 |
Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
Topics: Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Photochemotherapy | 2020 |
Localized leishmaniasis treated with intralesional meglumine antimoniate.
Topics: Antiprotozoal Agents; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Treatment Outcome | 2020 |
[Erysipeloid leishmaniasis].
Topics: Erysipeloid; Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate | 2020 |
A natural cell-penetrating nanopeptide combined with pentavalent antimonial as experimental therapy against cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Crotalid Venoms; Crotalus; Drug Combinations; Interleukin-12; Leishmania mexicana; Leishmaniasis, Cutaneous; Lymph Nodes; Macrophages, Peritoneal; Mass Spectrometry; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Nitric Oxide; Nitrites; Tumor Necrosis Factor-alpha | 2020 |
[Determination of Antimony Resistance Mechanism of Leishmania tropica Causing Cutaneous Leishmaniasis in Turkey].
Topics: Drug Resistance; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Turkey | 2020 |
Leishmaniasis: An Unforgettable Disease.
Topics: Adult; Antiprotozoal Agents; Forearm; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate | 2020 |
Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).
Topics: Antiprotozoal Agents; Humans; Leishmania; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Meglumine Antimoniate | 2021 |
Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
Topics: Animals; Leishmania; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Parasite Load; Vascular Endothelial Growth Factor A | 2020 |
Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Ulcer | 2021 |
Evaluating the effect of oral clarithromycin on acute cutaneous leishmaniasis lesions compared with systemic glucantime.
Topics: Antiprotozoal Agents; Clarithromycin; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2022 |
Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major.
Topics: Animals; Leishmania major; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C | 2020 |
Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mice; Phosphorylcholine | 2021 |
The potential therapeutic role of PTR1 gene in non-healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica.
Topics: Adult; Animals; Antiprotozoal Agents; DNA, Antisense; Drug Resistance, Microbial; Female; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mice, Inbred BALB C; Oxidoreductases; Protozoan Proteins; Transfection | 2021 |
Distribution, treatment outcome and genetic diversity of Leishmania species in military personnel from Colombia with cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Colombia; DNA, Protozoan; Genetic Variation; Haplotypes; HSP70 Heat-Shock Proteins; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Military Personnel; Pentamidine; Phylogeny; Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2020 |
Efficacy of nanoemulsion with Pterodon emarginatus Vogel oleoresin for topical treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Cytokines; Disease Models, Animal; Drug Compounding; Drug Therapy, Combination; Emulsions; Fabaceae; Female; Host-Parasite Interactions; Leishmania mexicana; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mesocricetus; Mice, Inbred BALB C; Nanoparticles; Parasite Load; Plant Extracts; Skin; Trypanocidal Agents | 2021 |
Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.
Topics: Adult; Antiprotozoal Agents; Case-Control Studies; Female; Humans; Leishmaniasis, Cutaneous; Logistic Models; Male; Meglumine Antimoniate; Middle Aged; Risk Factors; Treatment Failure | 2021 |
Major risk factors and histopathological profile of treatment failure, relapse and chronic patients with anthroponotic cutaneous leishmaniasis: A prospective case-control study on treatment outcome and their medical importance.
Topics: Adolescent; Case-Control Studies; Child; Chronic Disease; Female; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Polymerase Chain Reaction; Prospective Studies; Recurrence; Risk Factors; Treatment Failure; Treatment Outcome | 2021 |
Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by Leishmania braziliensis.
Topics: Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Obesity | 2021 |
The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Phosphorylcholine; Young Adult | 2021 |
Unusual manifestation of genital cutaneous leishmaniasis in an immunocompetent patient from São Paulo, Brazil: A case report.
Topics: Adult; Antiprotozoal Agents; Brazil; Genitalia; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction | 2021 |
Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Colombia; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Risk Factors; Treatment Failure; Young Adult | 2017 |
Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Topics: Administration, Oral; Antiprotozoal Agents; Caregivers; Child; Child, Preschool; Cost-Benefit Analysis; Directly Observed Therapy; Drug Costs; Female; Humans; Injections, Intramuscular; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Monte Carlo Method; Organometallic Compounds; Phosphorylcholine; Sensitivity and Specificity; Treatment Outcome; United States | 2017 |
Leishmaniasis of the Feet Sole: A Case Report.
Topics: Adult; Antiprotozoal Agents; Female; Foot Dermatoses; Forefoot, Human; Humans; Injections, Intramuscular; Iran; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2017 |
Leishmanial dactylitis: an unusual clinical presentation.
Topics: Aged; Antiprotozoal Agents; Diagnosis, Differential; Endemic Diseases; Female; Fingers; Humans; Iran; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Travel-Related Illness | 2017 |
Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2017 |
Amiodarone and itraconazole improve the activity of pentavalent antimonial in the treatment of experimental cutaneous leishmaniasis.
Topics: Amiodarone; Animals; Cricetinae; Disease Models, Animal; Drug Therapy, Combination; Hindlimb; Histocytochemistry; Itraconazole; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Skin; Treatment Outcome | 2017 |
Chemical Characterization, Antileishmanial Activity, and Cytotoxicity Effects of the Essential Oil from Leaves of Pluchea carolinensis (Jacq.) G. Don. (Asteraceae).
Topics: Animals; Antiprotozoal Agents; Asteraceae; Female; Leishmania; Leishmania mexicana; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Oils, Volatile; Organometallic Compounds; Plant Leaves | 2017 |
Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Brazil; Child; Cluster Analysis; Cohort Studies; DNA, Kinetoplast; Electrophoresis, Agar Gel; Female; Genotype; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phenotype; Pilot Projects; Polymerase Chain Reaction; Polymorphism, Genetic; Young Adult | 2017 |
Intralesional Infiltration with Meglumine Antimoniate for the Treatment of Leishmaniasis Recidiva Cutis in Ecuador.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Ecuador; Female; Follow-Up Studies; Humans; Injections, Intralesional; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Young Adult | 2017 |
Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
Topics: Adult; Antiprotozoal Agents; Cohort Studies; Female; Humans; Incidence; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Recurrence; Retrospective Studies; Treatment Outcome | 2017 |
In vivo studies of the effectiveness of novel N-halomethylated and non-halomethylated quaternary ammonium salts in the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Body Weight; Cricetinae; Disease Models, Animal; Female; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Quaternary Ammonium Compounds; Salts; Skin; Toxicity Tests | 2018 |
Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment.
Topics: Antiprotozoal Agents; Clinical Protocols; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Reproducibility of Results | 2018 |
Antimonial susceptibility and in vivo behaviour of Leishmania major isolates collected in Algeria before and after treatment.
Topics: Adult; Algeria; Animals; Antiprotozoal Agents; Drug Resistance, Microbial; Humans; Leishmania major; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Middle Aged; Organometallic Compounds; Treatment Failure; Young Adult | 2018 |
[Leishmaniasis of the eyelid masquerading as a chalazion: Case report].
Topics: Adult; Chalazion; Diagnosis, Differential; Eye Infections, Parasitic; Eyelid Diseases; Eyelids; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Morocco | 2018 |
Cutaneous Leishmaniasis in Pediatric Patients in a Single Tertiary Hospital in Ankara.
Topics: Antiprotozoal Agents; Child; Child Health Services; Child, Preschool; Female; Humans; Infant; Leishmania; Leishmaniasis, Cutaneous; Male; Medical Records; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Retrospective Studies; Tertiary Care Centers; Turkey | 2017 |
Arnica Tincture Cures Cutaneous Leishmaniasis in Golden Hamsters.
Topics: Animals; Antiprotozoal Agents; Arnica; Cricetinae; Dose-Response Relationship, Drug; Female; Lactones; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Mesocricetus; Plant Extracts; Structure-Activity Relationship | 2018 |
Biosynthesis, characterization and leishmanicidal activity of a biocomposite containing AgNPs-PVP-glucantime.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Humans; Leishmaniasis, Cutaneous; Macrophages; Meglumine Antimoniate; Metal Nanoparticles; Mice; Nanocomposites; Particle Size; Polyvinyls; Pyrrolidines; Silver | 2018 |
Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia.
Topics: Colombia; Cost-Benefit Analysis; Disabled Persons; Humans; Hyperthermia, Induced; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Epidemiological Aspects of Cutaneous Leishmaniasis during 2009-2016 in Kashan City, Central Iran.
Topics: Adolescent; Adult; Age Factors; Animals; Child; Child, Preschool; Disease Reservoirs; Disease Vectors; Female; Health Education; Humans; Incidence; Infant; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Seasons; Time Factors; Young Adult | 2018 |
Glucantime reduces mechanical hyperalgesia in cutaneous leishmaniasis and complete Freund's adjuvant models of chronic inflammatory pain.
Topics: Acetylglucosaminidase; Animals; Chronic Pain; Cytokines; Freund's Adjuvant; Inflammation; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Peroxidase; Skin | 2018 |
Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Biomarkers, Pharmacological; Child; Female; Gene Expression Profiling; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Young Adult | 2018 |
Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Microbial Sensitivity Tests; Organometallic Compounds; Pilot Projects; Practice Guidelines as Topic; Turkey | 2018 |
Meglumine antimoniate-induced DRESS: original case with a positive skin test.
Topics: Animals; Antiprotozoal Agents; Cryotherapy; Drug Hypersensitivity Syndrome; Eosinophilia; Exanthema; Female; Humans; Intradermal Tests; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Metronidazole; Middle Aged | 2018 |
Differential expression of TLRs 2, 4, 9, iNOS and TNF-α and arginase activity in peripheral blood monocytes from glucantime unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis caused by Leishmania tropica.
Topics: Adolescent; Adult; Arginase; Case-Control Studies; Child; Child, Preschool; Down-Regulation; Female; Gene Expression; Host-Parasite Interactions; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Monocytes; Nitric Oxide Synthase Type II; Toll-Like Receptor 10; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult | 2019 |
Investigation of the antimicrobial activity of a short cationic peptide against promastigote and amastigote forms of Leishmania major (MHRO/IR/75/ER): An in vitro study.
Topics: Animals; Antimicrobial Cationic Peptides; Antiprotozoal Agents; Coloring Agents; DNA, Protozoan; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Meglumine Antimoniate; Mice; RAW 264.7 Cells; Real-Time Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Trypan Blue | 2019 |
A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Child; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Humans; Interleukin-10; Interleukin-12 Subunit p40; Leishmania tropica; Leishmaniasis, Cutaneous; Levamisole; Macrophages; Male; Meglumine Antimoniate; Mice; Middle Aged; Nitric Oxide Synthase Type II; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2019 |
Resistance of
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Extracellular Traps; Humans; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Mice; Mice, Inbred C57BL; Neutrophils; Parasitic Sensitivity Tests; Phosphorylcholine; Primary Cell Culture; Reactive Oxygen Species | 2018 |
Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways.
Topics: Antiprotozoal Agents; Case-Control Studies; Cells, Cultured; Cytokines; Endemic Diseases; Female; Gene Expression Regulation; Humans; Inflammation Mediators; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Meglumine Antimoniate; Th1 Cells; Treatment Outcome | 2019 |
Cutaneous schistosomiasis and leishmaniasis coinfection: a case report.
Topics: Adult; Antiprotozoal Agents; Biopsy; Coinfection; Diagnosis, Differential; Female; Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Schistosomiasis; Skin Diseases, Parasitic | 2019 |
A Novel Niosomal Combination of Selenium Coupled with Glucantime against Leishmania tropica.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Cytokines; Drug Delivery Systems; Drug Synergism; Formazans; Gene Expression Profiling; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages; Meglumine Antimoniate; Mice; Parasitic Sensitivity Tests; Selenium; Tetrazolium Salts | 2019 |
Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antiprotozoal Agents; Brazil; Female; Humans; Injections, Intralesional; Injections, Intramuscular; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Primary Health Care; Treatment Outcome; Young Adult | 2019 |
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Topics: Amines; Analysis of Variance; Animals; Antiprotozoal Agents; Female; Leishmania major; Leishmaniasis, Cutaneous; Liposomes; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Rabbits; Spleen | 2019 |
Cutaneous Leishmaniasis caused by L. Infantum.
Topics: Adult; Animals; Female; Humans; Injections, Intralesional; Leishmania infantum; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Neglected Diseases; Polymerase Chain Reaction; Treatment Outcome | 2019 |
Simultaneous occurrence of cutaneous and mucocutaneous leishmaniasis caused by different genotypes of Leishmania (Viannia) braziliensis.
Topics: Adult; Antiprotozoal Agents; Argentina; Genotype; Genotyping Techniques; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate | 2019 |
Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
Topics: Adult; Antiprotozoal Agents; Child, Preschool; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Treatment Outcome; Young Adult | 2019 |
Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Cryotherapy; Female; Humans; Infant; Infant, Newborn; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Middle Aged; Risk Factors; Treatment Failure; Young Adult | 2019 |
Epidemiological Trend of Cutaneous Leishmaniasis in an Endemic Focus Disease During 2009-2016, Central Iran
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Cross-Sectional Studies; Cryotherapy; Endemic Diseases; Female; Humans; Incidence; Infant; Iran; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Microscopy; Middle Aged; Occupations; Seasons; Software; Young Adult | 2019 |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Brazil; Drug-Related Side Effects and Adverse Reactions; Humans; Leishmaniasis, Cutaneous; Male; Meglumine Antimoniate; Renal Dialysis; Renal Insufficiency, Chronic | 2019 |
Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil.
Topics: Amino Acid Substitution; Animals; Antiprotozoal Agents; Base Sequence; Brazil; DNA, Protozoan; Drug Resistance; Genetic Markers; HSP70 Heat-Shock Proteins; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Meglumine; Meglumine Antimoniate; Molecular Sequence Data; Mutation; Organometallic Compounds; Polymorphism, Genetic; Prognosis; Protozoan Proteins; Sequence Analysis, DNA; Treatment Outcome | 2013 |
In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
Topics: Antiprotozoal Agents; Cell Line; Cell Survival; Chitosan; Cicatrix; Drug Carriers; Excipients; Fibroblasts; Humans; Immunomodulation; Interleukins; Lactic Acid; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pilot Projects; Povidone; Wound Healing | 2013 |
Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Injections, Intralesional; Injections, Intramuscular; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study.
Topics: Antiprotozoal Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Liberation; Hydrophobic and Hydrophilic Interactions; Lactic Acid; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Microscopy, Electron, Scanning; Microspheres; Organometallic Compounds; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectrometry, X-Ray Emission; Spectroscopy, Fourier Transform Infrared; Surface Properties | 2014 |
Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Retrospective Studies; Species Specificity; Switzerland; Travel; Treatment Outcome; Young Adult | 2013 |
Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Apoptosis; Cytokines; DNA Fragmentation; Female; Immunologic Factors; Inhibitory Concentration 50; Leishmania major; Leishmaniasis, Cutaneous; Lignans; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Nitric Oxide; Organometallic Compounds | 2013 |
Cutaneous leishmaniasis "chiclero's ulcer" in subtropical Ecuador.
Topics: Administration, Topical; Adolescent; Antiprotozoal Agents; Ear; Ecuador; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin Ulcer; Thimerosal | 2013 |
Slow-growing scaly erythematous plaque on the face and scalp of an elderly woman.
Topics: Aged, 80 and over; Antibodies, Protozoan; Antiprotozoal Agents; Erythema; Facial Dermatoses; False Negative Reactions; Female; Humans; Inclusion Bodies; Leishmania infantum; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Scalp Dermatoses; Staining and Labeling | 2013 |
[Chronic facial ulceration in France and potential involvement of Leishmania infantum cutaneous leishmaniasis].
Topics: Antiprotozoal Agents; Child; Combined Modality Therapy; Cryotherapy; Facial Dermatoses; Female; France; Humans; Injections, Intralesional; Leishmania infantum; Leishmaniasis, Cutaneous; Mediterranean Region; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2013 |
Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: treatment with cryotherapy and intralesional meglumine antimonate.
Topics: Adult; Antiprotozoal Agents; Antirheumatic Agents; Arthritis, Psoriatic; Combined Modality Therapy; Cryotherapy; Humans; Infliximab; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2014 |
An atypical case of cutaneous leishmaniasis caused by Leishmania infantum in Portugal.
Topics: Aged; Antiprotozoal Agents; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Portugal | 2013 |
Nonhealing ulcers: an infectious viewpoint.
Topics: Antiprotozoal Agents; Biopsy; Diagnosis, Differential; Female; Humans; Iran; Leg Ulcer; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Wound Healing | 2014 |
[Cutaneous leishmaniasis and multidermatomic herpes zoster].
Topics: Adult; Antiprotozoal Agents; Female; Herpes Zoster; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin Diseases, Viral | 2013 |
Effects of combined therapy with silymarin and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Topics: Animals; Drug Therapy, Combination; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Silymarin | 2015 |
The influence of treatment on the development of leishmaniasis recidiva cutis: a 17-year case-control study in Midwestern Brazil.
Topics: Adolescent; Adult; Amphotericin B; Brazil; Case-Control Studies; Female; Humans; Incidence; Leishmaniasis, Cutaneous; Longitudinal Studies; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentamidine; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Trypanocidal Agents; Young Adult | 2015 |
Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Cell Line; Female; Leishmania major; Leishmaniasis, Cutaneous; Liposomes; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Random Allocation; Skin; Spleen | 2014 |
Co-existence of cutaneous leishmaniasis with pleural effusion: a case report from Iran.
Topics: Antiprotozoal Agents; Antitubercular Agents; Child; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pleural Effusion; Polymerase Chain Reaction; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2014 |
Cutaneous Leishmaniasis with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; HIV Infections; Humans; Immunocompromised Host; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2014 |
Heterogeneity of molecular resistance patterns in antimony-resistant field isolates of Leishmania species from the western Mediterranean area.
Topics: Algeria; Antiprotozoal Agents; Drug Resistance; France; Gene Expression Regulation; Genotype; Humans; Leishmania infantum; Leishmania major; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Metabolic Networks and Pathways; Organometallic Compounds; Parasitic Sensitivity Tests; Phenotype; Protozoan Proteins; Tunisia | 2014 |
In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Phosphorylcholine; Spleen | 2014 |
A 45 year old man with an ulcerated nodule on his right leg.
Topics: Antiprotozoal Agents; Humans; Injections, Intralesional; Leg Ulcer; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2014 |
Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Lebanon; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Refugees; Syria; Young Adult | 2014 |
[Four cutaneous leishmaniosis case resistant to meglumine antimoniate treatment].
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Diptera; DNA, Intergenic; DNA, Protozoan; Drug Resistance; Humans; Larva; Leishmania; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2014 |
[Clinical, epidemiological and evolutionary aspects in 157 cases of cutaneous leishmaniasis in Morocco].
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Cicatrix; Disease Progression; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Morocco; Nitrogen; Organometallic Compounds; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Cutaneous leishmaniasis: 20 years' experience in a Spanish tertiary care hospital.
Topics: Adolescent; Adult; Africa, Northern; Aged; Antiprotozoal Agents; Comorbidity; Emigrants and Immigrants; Endemic Diseases; Female; HIV Infections; Humans; Immunocompromised Host; Latin America; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Spain; Tertiary Care Centers; Young Adult | 2015 |
Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Topics: 3' Untranslated Regions; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Aquaglyceroporins; Aquaporin 1; Cell Movement; Drug Resistance; Gene Expression Regulation; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; RNA, Messenger; RNA, Protozoan | 2015 |
[Facial inflammatory cutaneous leishmaniasis or "erysipeloid"].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiprotozoal Agents; Erysipeloid; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Postmenopause | 2015 |
Apoptosis and frequency of total and effector CD8+ T lymphocytes from cutaneous leishmaniasis patients during antimonial therapy.
Topics: Adult; Antigens, Protozoan; Antiprotozoal Agents; Apoptosis; Brazil; CD8-Positive T-Lymphocytes; Cohort Studies; Female; Flow Cytometry; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Young Adult | 2015 |
In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Line, Tumor; Child; Humans; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages; Male; Meglumine; Meglumine Antimoniate; Naphthoquinones; Organometallic Compounds; Pakistan; Parasitic Sensitivity Tests | 2015 |
[Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
Topics: Administration, Intravenous; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Injections, Intralesional; Injections, Intramuscular; Insect Bites and Stings; Insect Vectors; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phlebotomus | 2015 |
Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran.
Topics: Antiprotozoal Agents; Child; Female; Humans; Injections, Intralesional; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Outcome Assessment, Health Care; Surveys and Questionnaires; Treatment Outcome | 2015 |
[Three Pediatric Cases of Leishmaniasis with Different Clinical Forms and Treatment Regimens].
Topics: Amphotericin B; Antiprotozoal Agents; Child, Preschool; Humans; Iran; Iraq; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Turkey | 2015 |
Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Retrospective Studies; Young Adult | 2016 |
The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Interleukin-10; Interleukin-12; Interleukin-1beta; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; NF-kappa B; Organometallic Compounds; Phenyl Ethers; Quinazolines; Signal Transduction | 2015 |
Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
Topics: Animals; Antiprotozoal Agents; Chitosan; Female; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Treatment Outcome | 2015 |
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome | 2015 |
[Erysipeloid cutaneous leishmaniasis: about a clinical observation].
Topics: Adult; Antiprotozoal Agents; Erysipeloid; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Nose Diseases; Organometallic Compounds | 2015 |
Cutaneous leishmaniasis mimicking granulomatous cheilitis and treated successfully with oral fluconazole in a boy.
Topics: Antiprotozoal Agents; Child; Diagnosis, Differential; Fluconazole; Humans; Leishmaniasis, Cutaneous; Lip; Male; Meglumine; Meglumine Antimoniate; Melkersson-Rosenthal Syndrome; Organometallic Compounds; Treatment Outcome | 2015 |
Propolis reduces Leishmania amazonensis-induced inflammation in the liver of BALB/c mice.
Topics: Animals; Cytokines; Inflammation; Leishmania mexicana; Leishmaniasis, Cutaneous; Liver; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Propolis | 2016 |
Tumour Necrosis Factor-alpha (TNF-α) and its soluble receptor type 1 (sTNFR I) in human active and healed leishmaniases.
Topics: Adult; Antiprotozoal Agents; Case-Control Studies; Female; Humans; Interleukin-17; Interleukin-22; Interleukins; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Receptors, Tumor Necrosis Factor, Type I; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
In Vitro and In Vivo Antileishmanial Activities of Pistacia vera Essential Oil.
Topics: Animals; Antiprotozoal Agents; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Oils, Volatile; Organometallic Compounds; Pistacia | 2016 |
Cutaneous Leishmaniasis: An Overlooked Etiology of Midfacial Destructive Lesions.
Topics: Adolescent; Adult; Biopsy; Child; Child, Preschool; Female; Humans; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Nose; Nose Diseases; Organometallic Compounds; Polymerase Chain Reaction; Young Adult | 2016 |
Cytotoxic cell involvement in human cutaneous leishmaniasis: assessments in active disease, under therapy and after clinical cure.
Topics: Adult; Antiprotozoal Agents; CD4 Lymphocyte Count; Cell Degranulation; Cells, Cultured; Cytotoxicity, Immunologic; Female; Humans; Killer Cells, Natural; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Natural Killer T-Cells; Organometallic Compounds; Young Adult | 2016 |
Development of a Murine Infection Model with Leishmania killicki, Responsible for Cutaneous Leishmaniosis in Algeria: Application in Pharmacology.
Topics: Algeria; Animals; Disease Models, Animal; Humans; Leishmania infantum; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Organometallic Compounds; Spleen | 2016 |
AMERICAN CUTANEOUS LEISHMANIASIS WITH UNUSUAL CLINICAL PRESENTATION AND RESPONSE TO TREATMENT.
Topics: Amphotericin B; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2016 |
Two small yellowish papules in a 1 year-old boy: cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Facial Dermatoses; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin | 2016 |
In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.
Topics: Adult; Aged; Animals; Antiprotozoal Agents; Brazil; Complement System Proteins; Cytokines; DNA, Protozoan; Female; Guinea Pigs; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Middle Aged; Nitric Oxide; Organometallic Compounds; Random Amplified Polymorphic DNA Technique | 2016 |
Allergic reactions to meglumine antimoniate while treating cutaneous leishmaniasis.
Topics: Adult; Drug Hypersensitivity; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2017 |
Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Topics: Adult; Antiprotozoal Agents; Cohort Studies; Cross-Sectional Studies; Humans; Inhibitory Concentration 50; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Treatment Failure; U937 Cells; Young Adult | 2016 |
Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Female; Hydrophobic and Hydrophilic Interactions; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; Microscopy, Atomic Force; Nanoparticles; Organometallic Compounds; Scattering, Small Angle; Solvents; Treatment Outcome; X-Ray Diffraction | 2016 |
Expression analysis of activated protein kinase C gene (LACK1) in antimony sensitive and resistant Leishmania tropica clinical isolates using real-time RT-PCR.
Topics: Antiprotozoal Agents; Cross-Sectional Studies; Down-Regulation; Drug Resistance; Gene Expression; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Protein Kinase C; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2016 |
[Polymorphic lesions of cutaneous leishmaniasis revealing human immunodeficiency virus infection].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Endemic Diseases; Female; Fluconazole; Herpes Zoster; Humans; Immunocompromised Host; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Morocco; Organometallic Compounds; Recurrence; Viremia; Young Adult | 2016 |
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Long-standing Erythematous Plaque in a Perianal Skin Fold.
Topics: Aged, 80 and over; Antiprotozoal Agents; Buttocks; Erythema; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2017 |
Topical Treatment of Leishmania tropica Infection Using (-)-α-Bisabolol Ointment in a Hamster Model: Effectiveness and Safety Assessment.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cricetinae; Cytochrome P-450 CYP2D6 Inhibitors; Disease Models, Animal; Injections, Intralesional; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Molecular Structure; Monocyclic Sesquiterpenes; Organometallic Compounds; Sesquiterpenes; Skin; Stereoisomerism | 2016 |
DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.
Topics: Administration, Cutaneous; Animals; Antiprotozoal Agents; Cellulose; Cytokines; Ditiocarb; Drug Therapy, Combination; Female; Gluconacetobacter; Humans; Injections, Intraperitoneal; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Primary Cell Culture; Superoxide Dismutase-1; Superoxides | 2016 |
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Injections, Intralesional; Lasers, Dye; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2017 |
Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.
Topics: Adolescent; Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Brazil; Cochlea; Female; Hearing; Humans; Leishmaniasis, Cutaneous; Longitudinal Studies; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Otoacoustic Emissions, Spontaneous; Prospective Studies; Young Adult | 2017 |
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Female; Firefly Luciferin; Fluconazole; Genes, Reporter; High-Throughput Screening Assays; Leishmania major; Leishmaniasis, Cutaneous; Luciferases; Luminescent Measurements; Macrophages; Meglumine; Meglumine Antimoniate; Mesocricetus; Mice; Mice, Inbred BALB C; Ofloxacin; Optical Imaging; Organisms, Genetically Modified; Organometallic Compounds; Triazoles | 2017 |
Evolution of cutaneous leishmaniasis in the last 30 years in a tertiary hospital of the European Mediterranean coast.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Factors; Aged; Amphotericin B; Antiprotozoal Agents; Female; Humans; Immunocompromised Host; Kidney Transplantation; Leishmaniasis, Cutaneous; Male; Mediterranean Region; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Severity of Illness Index; Tertiary Care Centers; Tumor Necrosis Factor-alpha | 2017 |
Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Ethanol; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Luciferases; Luminescence; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Skin; Skin Cream; Tamoxifen | 2018 |
Activity of hydroxyurea against Leishmania mexicana.
Topics: Animals; Antiprotozoal Agents; Cell Cycle; Disease Models, Animal; Humans; Hydroxyurea; In Vitro Techniques; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests | 2008 |
Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Topics: Adolescent; Amphotericin B; Animals; Antiprotozoal Agents; Female; Humans; Interferon-gamma; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phosphorylcholine | 2008 |
Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Topics: Administration, Topical; Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Trichloroacetic Acid | 2008 |
[Outbreak of cutaneous leishmaniasis: about 213 cases in the province of Tizi-Ouzou].
Topics: Adolescent; Adult; Aged; Algeria; Antiprotozoal Agents; Child; Child, Preschool; Disease Outbreaks; Endemic Diseases; Facial Dermatoses; Female; Humans; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Young Adult | 2009 |
Cutaneous leishmaniasis imported from Colombia to Northcentral Venezuela: implications for travel advice.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Colombia; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Travel; Treatment Outcome; Venezuela; Young Adult | 2008 |
Antileishmanial activity of 1,3,4-thiadiazolium-2-aminide in mice infected with Leishmania amazonensis.
Topics: Animals; Antiprotozoal Agents; Blood Cell Count; Leishmania mexicana; Leishmaniasis, Cutaneous; Lymph Nodes; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred CBA; Nitric Oxide; Organometallic Compounds; Structure-Activity Relationship; Thiadiazoles | 2009 |
The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Colombia; Female; Humans; Hyperthermia, Induced; Infant; Infant, Newborn; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prospective Studies; Treatment Outcome; Young Adult | 2009 |
[Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Tunisia; Young Adult | 2008 |
Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime.
Topics: Administration, Oral; Adult; Animals; Antimony; Antiprotozoal Agents; Atrial Premature Complexes; Bradycardia; Bundle-Branch Block; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prognosis; Prospective Studies; Ventricular Premature Complexes | 2008 |
Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.
Topics: Animals; Antigens, Protozoan; Case-Control Studies; Concanavalin A; Female; Follow-Up Studies; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-10; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Statistics, Nonparametric; Treatment Outcome | 2009 |
Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice.
Topics: Achillea; Administration, Cutaneous; Animals; Antiprotozoal Agents; Female; Injections, Intraperitoneal; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Phytotherapy; Plant Extracts; Propolis; Thymus Plant; Treatment Outcome | 2008 |
Localized cutaneous leishmaniasis of the plantar region: a 40-year outcome.
Topics: Aged; Animals; Antiprotozoal Agents; DNA, Protozoan; Drug Administration Schedule; Foot; Gene Amplification; Humans; Injections, Intravenous; Leishmania; Leishmaniasis, Cutaneous; Male; Medical Records; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2008 |
Childhood cutaneous leishmaniasis: Experience of a Moroccan unit of dermatology.
Topics: Antiprotozoal Agents; Child; Dermatology; Face; Female; Hospitals, University; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Morocco; Organometallic Compounds; Retrospective Studies; Sex Distribution; Treatment Outcome | 2008 |
[Cutaneous leishmaniasis in rheumatoid arthritis].
Topics: Adult; Antiprotozoal Agents; Arthritis, Rheumatoid; Female; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Methotrexate; Middle Aged; Organometallic Compounds; Prednisone | 2009 |
Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Ethiopia; Female; HIV Infections; HIV-1; Humans; Infant; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentamidine; Socioeconomic Factors; Young Adult | 2009 |
Rhinophymous leishmaniasis: A new variant.
Topics: Aged; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Rhinophyma | 2009 |
[Raised tattoos in a human-immunodeficiency-virus-infected patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Hepatitis C, Chronic; Histiocytes; Humans; Lamivudine; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Lopinavir; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Patient Compliance; Pentamidine; Pyrimidinones; Recurrence; Ritonavir; Tattooing; Zidovudine | 2009 |
Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil.
Topics: Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Brazil; Facial Dermatoses; Female; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pregnancy; Pregnancy Complications, Parasitic; Prognosis; Risk Assessment; Risk Factors; Treatment Outcome; Young Adult | 2009 |
The potential utility of green tea extract as a novel treatment for cutaneous leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Camellia sinensis; Drug Resistance; Flavonoids; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Phenols; Phytotherapy; Plant Extracts; Polyphenols; Tea | 2009 |
[Mucosal complication of cutaneous leishmaniasis].
Topics: Aged; Anemia; Antiprotozoal Agents; Contraindications; Eyelid Diseases; Humans; Hypertension; Kidney Failure, Chronic; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Lip Diseases; Male; Meglumine; Meglumine Antimoniate; Nose Diseases; Organometallic Compounds; Phosphorylcholine | 2009 |
Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).
Topics: Animals; Antimony; Antiprotozoal Agents; Kidney; Leishmania braziliensis; Leishmaniasis, Cutaneous; Liver; Macaca mulatta; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spleen | 2010 |
In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Humans; Leishmania braziliensis; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests | 2010 |
Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
Topics: Antibodies, Monoclonal; Antiprotozoal Agents; Antirheumatic Agents; Humans; Infliximab; Leishmania infantum; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Spondylitis, Ankylosing; Tumor Necrosis Factor-alpha | 2010 |
Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
Topics: Adult; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Female; Humans; Leishmaniasis, Cutaneous; Male; Mass Spectrometry; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin; Treatment Outcome | 2009 |
Cutaneous leishmaniasis of the lid: a report of nine cases.
Topics: Adolescent; Adult; Child; Eyelid Diseases; Eyelids; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2010 |
American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil.
Topics: Age Factors; Aged; Aged, 80 and over; Antiprotozoal Agents; Brazil; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2010 |
[Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Child; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Treatment Outcome | 2010 |
A case with two unusual findings: cutaneous leishmaniasis presenting as panniculitis and pericarditis after antimony therapy.
Topics: Antiprotozoal Agents; Chest Pain; DNA, Protozoan; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Panniculitis; Pericarditis | 2010 |
Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes.
Topics: Animals; Antimony; Antiprotozoal Agents; Brazil; Drug Resistance; Gene Expression Profiling; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasites; Treatment Outcome | 2010 |
Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006.
Topics: Adolescent; Allopurinol; Child; Face; Female; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prevalence | 2010 |
Childhood and adult cutaneous leishmaniasis in Tunisia.
Topics: Adolescent; Adult; Age Distribution; Age of Onset; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Sex Distribution; Tunisia; Young Adult | 2010 |
Glucantime fever with parenteral meglumine antimonate in patients of cutaneous leishmaniasis.
Topics: Antimony; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2010 |
Leishmania amazonensis META2 protein confers protection against heat shock and oxidative stress.
Topics: Animals; Antiprotozoal Agents; Blotting, Western; Fluorescent Antibody Technique; Gene Expression Regulation; Hot Temperature; Leishmania mexicana; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Mutation; Novobiocin; Nucleic Acid Synthesis Inhibitors; Organometallic Compounds; Oxidative Stress; Protozoan Proteins; Recombinant Proteins; RNA Interference; Trypanosoma brucei brucei | 2011 |
Lupoid leishmaniasis due to Leishmania major with remaining large scars: report of 2 cases.
Topics: Adolescent; Adult; Antiprotozoal Agents; Chronic Disease; Cicatrix; Diagnosis, Differential; Humans; Iran; Leishmania major; Leishmaniasis, Cutaneous; Lupus Vulgaris; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recurrence; Treatment Outcome | 2010 |
Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.
Topics: Adult; Antimony; Antiprotozoal Agents; Cytokines; Female; Humans; Interferon-gamma; Interleukin-10; Leishmaniasis, Cutaneous; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regeneration; Skin; Transforming Growth Factor beta; Treatment Failure | 2011 |
Unusual form of cutaneous leishmaniasis: erysipeloid form.
Topics: Antiprotozoal Agents; Biopsy; Diagnosis, Differential; Erysipeloid; Facial Dermatoses; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Middle Aged; Nose; Nose Diseases; Organometallic Compounds; Polymerase Chain Reaction; Skin | 2011 |
[Bilateral chronic and granulomatous total uveitis following cutaneous leishmaniasis].
Topics: Adolescent; Anti-Inflammatory Agents; Antiprotozoal Agents; Female; Granuloma; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Methylprednisolone; Organometallic Compounds; Panuveitis; Prednisone | 2011 |
Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Female; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2011 |
Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminoquinolines; Animals; Antigens, CD; Antigens, CD1; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antiprotozoal Agents; B-Lymphocytes; CD3 Complex; Child; Dermis; Drug Therapy, Combination; Epidermis; Female; Humans; Imiquimod; Iran; Langerhans Cells; Leishmania tropica; Leishmaniasis, Cutaneous; Lymphocyte Count; Macrophages; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Parasite Load; Single-Blind Method; T-Lymphocytes; Young Adult | 2011 |
An experimental approach to studying the effectiveness and safety of meglumine antimoniate formulations.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Immunomodulation; In Vitro Techniques; Injections, Intramuscular; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Organometallic Compounds; Species Specificity; Toxicity Tests | 2011 |
Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Cell Membrane; Cell Membrane Permeability; Cyclophosphamide; Erythrocytes; Fabaceae; Flow Cytometry; Humans; Injections, Subcutaneous; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Membrane Potentials; Mice; Mice, Inbred BALB C; Micronucleus Tests; Microscopy, Electron, Scanning; Mitochondria; Mutagens; Organometallic Compounds; Plant Oils | 2011 |
Cutaneous leishmaniasis with pseudoepitheliomatous hyperplasia simulating squamous cell carcinoma.
Topics: Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Epithelial Cells; Humans; Hyperplasia; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2011 |
The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.
Topics: Animals; Antiprotozoal Agents; Calcium Channel Blockers; Colorimetry; Disease Models, Animal; Drug Synergism; Inhibitory Concentration 50; Leishmania tropica; Leishmaniasis, Cutaneous; Macrophages, Peritoneal; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitic Sensitivity Tests; Verapamil | 2012 |
The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Leishmania infantum; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Thiadiazoles; Treatment Outcome | 2012 |
Treatment of imported New World cutaneous leishmaniasis in Germany.
Topics: Adolescent; Adult; Aged; Amphotericin B; Animals; Antiprotozoal Agents; Female; Germany; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Phosphorylcholine; Travel; Young Adult | 2011 |
Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Topics: Animals; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Erythrocytes; Female; Half-Life; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macaca mulatta; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Oxidation-Reduction; Reproducibility of Results; Spectrophotometry, Atomic; Thyroid Gland; Tissue Distribution | 2012 |
Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Azure Stains; DNA, Protozoan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasite Load; Phosphorylcholine; Time Factors; Ulcer | 2012 |
Infiltrated leishmaniasis recidivans cutis on the face: a rare clinical presentation.
Topics: Antiprotozoal Agents; Child; Diagnosis, Differential; Facial Dermatoses; Humans; Leishmania; Leishmaniasis, Cutaneous; Lupus Erythematosus, Discoid; Lupus Vulgaris; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Treatment Outcome | 2012 |
Cutaneous and mucocutaneous leishmaniasis resembling borderline-tuberculoid leprosy: a new clinical presentation?
Topics: Adolescent; Antiprotozoal Agents; Diagnosis, Differential; Endemic Diseases; Ethiopia; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Leprosy, Tuberculoid; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Young Adult | 2013 |
Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients.
Topics: Antiprotozoal Agents; Cells, Cultured; Drug Resistance, Microbial; Electrophoresis, Gel, Two-Dimensional; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Proteomics | 2012 |
Renal function evaluation in patients with American cutaneous leishmaniasis after specific treatment with pentavalent antimonial.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Kidney; Kidney Diseases; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Female; Humans; Injections, Intralesional; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Statistics, Nonparametric; Urban Population; Young Adult | 2012 |
Meglumine antimonate treatment enhances phagocytosis and TNF-α production by monocytes in human cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Brazil; Female; Humans; Hydrogen Peroxide; Interleukin-10; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Monocytes; Organometallic Compounds; Phagocytosis; Tumor Necrosis Factor-alpha | 2012 |
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Antiprotozoal Agents; Child; Child, Preschool; Cross-Sectional Studies; Erythema; Female; Humans; Infant; Injections, Intralesional; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pain; Pruritus; Treatment Outcome; Vomiting; Young Adult | 2012 |
Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab.
Topics: Adalimumab; Antibodies, Antinuclear; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Granuloma; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Methotrexate; Middle Aged; Organometallic Compounds | 2012 |
Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis.
Topics: Adult; Aged; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Skin Tests | 2012 |
Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure.
Topics: Antigens, Protozoan; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Humans; Interferon-gamma; Interleukin-10; Interleukin-4; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Tumor Necrosis Factor-alpha | 2012 |
Early enlargement of an ulcerated area during leishmaniasis treatment with meglumine antimoniate in Brazil.
Topics: Antiprotozoal Agents; Brazil; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Outcome Assessment, Health Care; Skin Ulcer | 2013 |
Unusual location of cutaneous leishmaniasis on the hallux in a Brazilian patient.
Topics: Aged; Animals; Antiprotozoal Agents; Female; Hallux; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Radiography | 2002 |
Expansion of gammadelta T Cells in patients infected with cutaneous leishmaniasis with and without glucantime therapy.
Topics: Adult; Aged; Antiprotozoal Agents; Case-Control Studies; Female; Flow Cytometry; Humans; Leishmaniasis, Cutaneous; Lymphocyte Activation; Lymphocyte Count; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; T-Lymphocyte Subsets | 2002 |
Human cutaneous leishmaniasis due to Leishmania infantum in the Sidi Bourouis focus (Northern Tunisia): epidemiological study and isoenzymatic characterization of the parasites.
Topics: Aged; Animals; Cells, Cultured; Child, Preschool; Female; Humans; Isoenzymes; Leishmania infantum; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Tunisia | 2003 |
Leishmaniasis of the lip.
Topics: Aged; Antiprotozoal Agents; Azure Stains; Humans; Leishmaniasis, Cutaneous; Lip Diseases; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2002 |
Post-kala-azar dermal leishmaniasis associated with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2002 |
American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
Topics: Administration, Oral; Antiprotozoal Agents; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentoxifylline; Tumor Necrosis Factor-alpha | 2003 |
Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
Topics: Adolescent; Antimony; Antiprotozoal Agents; Equipment Design; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2003 |
High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls.
Topics: Antiprotozoal Agents; Arsenic; Cadmium; Case-Control Studies; Chi-Square Distribution; Drug Contamination; Female; Humans; Hydrogen-Ion Concentration; Lead; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Metals, Heavy; Organometallic Compounds; Osmolar Concentration; Statistics, Nonparametric | 2003 |
Detection of new endemic areas of cutaneous leishmaniasis in Pakistan: a 6-year study.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Endemic Diseases; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pakistan | 2003 |
Back from the Peace Corps--with skin lesions from South America.
Topics: Adult; Animals; Antiprotozoal Agents; Diagnosis, Differential; Ecuador; Female; Government Agencies; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Time Factors; Treatment Outcome | 2003 |
Efficacy of 8-bromoguanosine against murine cutaneous leishmaniasis induced with Leishmania amazonensis.
Topics: Alanine Transaminase; Animals; Female; Guanosine; Hematologic Tests; Injections, Intraperitoneal; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred CBA; Organometallic Compounds; Skin Ulcer; Trypanocidal Agents; Urea | 2003 |
The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Aged; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Combined Modality Therapy; Cryotherapy; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome | 2003 |
[The activity of intramuscular glucantime and of intravenous anthiomaline in the treatment of sylvan American leishmaniasis].
Topics: Antimony; Furans; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1955 |
Rare variants of Cutaneous Leishmaniasis: whitlow, paronychia, and sporotrichoid.
Topics: Antiprotozoal Agents; Arm; Cryotherapy; Female; Fingers; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pakistan; Paronychia; Sporotrichosis | 2003 |
[Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate].
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Djibouti; Drug Resistance; France; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds | 2003 |
Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; beta-Cyclodextrins; Chemical Phenomena; Chemistry, Physical; Cyclodextrins; Injections, Intraperitoneal; Intestinal Absorption; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds | 2004 |
[Treatment of cutaneous leishmaniasis by antimoniate of N-methyl glucamine; 15 personal observations].
Topics: Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1950 |
[American cutaneo-mucous leishmaniasis; glucantime therapy; preliminary note].
Topics: Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; United States | 1951 |
Multiple leg ulcers in a traveler.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Azure Stains; Biopsy; Humans; Leg Ulcer; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Travel | 2004 |
Detection of pathogenic bacteria in skin lesions of patients with chiclero's ulcer. Reluctant response to antimonial treatment.
Topics: Antiprotozoal Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin Ulcer | 2003 |
Use of meglumine antimoniate in canine leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Humans; Infant; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2004 |
Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Animals; Antimony; Antiprotozoal Agents; Child; Child, Preschool; Cryosurgery; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Turkey | 2004 |
Emergency initiative to reduce leishmaniasis in Afghanistan.
Topics: Afghanistan; Antimony Sodium Gluconate; Antiprotozoal Agents; Bedding and Linens; Emergency Medical Services; Health Education; Humans; Incidence; International Cooperation; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pesticides; Refugees | 2004 |
Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Topics: Adolescent; Adult; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antiprotozoal Agents; Brazil; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique, Indirect; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin Tests | 2005 |
Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Topics: Administration, Topical; Animals; Antimony Sodium Gluconate; Cricetinae; Female; Gels; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Random Allocation; Statistics, Nonparametric | 2005 |
[Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2004 |
[Glucantime injection: benefit versus toxicity].
Topics: Aged; Aged, 80 and over; Antimony; Antiprotozoal Agents; Exanthema; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pain; Retrospective Studies | 2005 |
Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Biopsy; Brazil; Child; DNA, Protozoan; Female; Fluorescent Antibody Technique, Indirect; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Polymerase Chain Reaction; Sensitivity and Specificity; Skin Tests | 2005 |
Serum antioxidant activities, malondialdehyde and nitric oxide levels in human cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antioxidants; Antiprotozoal Agents; Child; Child, Preschool; Female; Glutathione Peroxidase; Humans; Leishmaniasis, Cutaneous; Lipid Peroxidation; Male; Malondialdehyde; Meglumine; Meglumine Antimoniate; Middle Aged; Nitric Oxide; Organometallic Compounds; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species; Superoxide Dismutase | 2005 |
[Slowly progressing skin ulcers following a stay in Costa Rica].
Topics: Adult; Animals; Antiprotozoal Agents; Costa Rica; Disease Progression; DNA, Protozoan; Facial Dermatoses; Hand Dermatoses; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; RNA, Protozoan; RNA, Ribosomal; Skin Ulcer; Spain; Travel | 2005 |
Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2005 |
Symmetrical cutaneous leishmaniasis.
Topics: Adult; Aged; Animals; Antiprotozoal Agents; Diagnosis, Differential; Extremities; Female; Humans; Injections, Intralesional; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2005 |
[The cutaneous leishmaniasis of the face in Gafsa area, Tunisia].
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Child; Child, Preschool; Disease Outbreaks; Endemic Diseases; Facial Dermatoses; Female; Humans; Incidence; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Necrosis; Nose Diseases; Organometallic Compounds; Prospective Studies; Skin Ulcer; Tunisia | 2005 |
Psoriasiform cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Diagnosis, Differential; Elbow; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Psoriasis | 2006 |
Refractory cutaneous leishmaniasis in an adolescent: initial manifestation of type 1 diabetes.
Topics: Adolescent; Antimony; Antiprotozoal Agents; Blood Glucose; Diabetes Mellitus, Type 1; Female; Humans; Knee; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2006 |
Cutaneous lupoid leishmaniasis: a case report.
Topics: Aged; Antiprotozoal Agents; Diagnosis, Differential; Face; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2006 |
[Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Disease Susceptibility; Drug Eruptions; Facial Dermatoses; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Retrospective Studies; Risk Assessment; Sporotrichosis; Staphylococcal Skin Infections; Superinfection | 2006 |
Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Topics: Adolescent; Adult; Animals; Antimony; Antiprotozoal Agents; Child; Drug Resistance; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Parasitic Sensitivity Tests; Treatment Failure; U937 Cells | 2006 |
Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Diagnosis, Differential; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2006 |
Cryotherapy as an adjunct to systemic antimonials for cutaneous leishmaniasis in children.
Topics: Adolescent; Antiprotozoal Agents; Child; Combined Modality Therapy; Cryotherapy; Dose-Response Relationship, Drug; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Skin | 2006 |
Pseudomonas aeruginosa otochondritis complicating localized cutaneous leishmaniasis: prevention of mutilation by early antibiotic therapy.
Topics: Adult; Animals; Anti-Infective Agents; Antimony; Antiprotozoal Agents; Cartilage; Ciprofloxacin; Ear, External; Humans; Immunocompetence; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pseudomonas Infections; Rifampin | 2006 |
The therapeutic effect of combined cryotherapy, paramomycin, and intralesional meglumine antimoniate in treating lupoid leishmaniasis and chronic leishmaniasis.
Topics: Adolescent; Adult; Amebicides; Child; Child, Preschool; Chronic Disease; Combined Modality Therapy; Cryotherapy; Drug Therapy, Combination; Female; Humans; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Paromomycin | 2006 |
Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Topics: Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Bolivia; Drugs, Generic; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Treatment Outcome | 2006 |
Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Immunity, Cellular; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Macaca mulatta; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2005 |
Childhood cutaneous leishmaniasis: report of 117 cases from Iran.
Topics: Adolescent; Animals; Antiprotozoal Agents; Child; Endemic Diseases; Female; Humans; Iran; Leishmania major; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Prevalence | 2006 |
Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
Topics: Adult; Antimony; Area Under Curve; Child; Child, Preschool; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Metabolic Clearance Rate; Organometallic Compounds; Plasma | 2007 |
Leishmania (Viannia) braziliensis infection in two Colombian dogs: a note on infectivity for sand flies and response to treatment.
Topics: Animals; Antiprotozoal Agents; Colombia; Dog Diseases; Dogs; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Psychodidae | 2006 |
A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Topics: Animals; Antigens, Protozoan; Antiprotozoal Agents; Cytokines; Drug Therapy, Combination; Immunoglobulin G; Immunologic Factors; Immunotherapy; Interferon-gamma; Interleukin-10; Interleukin-4; Leishmania mexicana; Leishmaniasis, Cutaneous; Lipids; Mannans; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Organometallic Compounds; Polysaccharides | 2007 |
Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Topics: Animals; Antimony; Antiprotozoal Agents; Geography; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Peru; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Species Specificity; Treatment Failure | 2007 |
Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiprotozoal Agents; Cardiotonic Agents; Cardiovascular Diseases; Drug Interactions; Electrocardiography; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Multivariate Analysis; Organometallic Compounds; Retrospective Studies | 2007 |
Disseminated cutaneous leishmaniasis: a patient with 749 lesions.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2006 |
An HIV-positive man with tattoo induration.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antiprotozoal Agents; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; HIV Seropositivity; Humans; Immunohistochemistry; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentamidine; Recurrence; Risk Assessment; Tattooing | 2007 |
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Iran; Leishmania tropica; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine | 2007 |
Dry type leishmanial lymphadenitis presented as two large parotid and cervical masses.
Topics: Animals; Antiprotozoal Agents; Female; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Lymphadenitis; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Skin | 2007 |
Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Topics: Animals; Antimony; Antiprotozoal Agents; Humans; Inhibitory Concentration 50; Leishmania braziliensis; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Treatment Outcome | 2007 |
Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
Topics: Adolescent; Adult; Allopurinol; Animals; Antimetabolites; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Face; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Recurrence; Treatment Outcome | 2007 |
Case report: Leishmaniasis of the upper lip.
Topics: Aged; Antiprotozoal Agents; Diagnosis, Differential; Humans; Leishmaniasis, Cutaneous; Lip; Lip Diseases; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2007 |
[Clinical and histological study of lupoid cutaneous leishmaniasis (16 cases)].
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Biopsy; Child; Disease Progression; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Skin; Time Factors; Treatment Outcome | 2007 |
Efficacy of the intralesional treatment with Chenopodium ambrosioides in the murine infection by Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chenopodium ambrosioides; Injections, Intralesional; Leishmania; Leishmaniasis, Cutaneous; Lymph Nodes; Male; Medicine, Traditional; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred C3H; Nitric Oxide; Organometallic Compounds; Plant Extracts; Plant Leaves | 2008 |
Mutilating lupoid leishmaniasis: twelve years to make the diagnosis!
Topics: Adult; Animals; Antimony; Antiprotozoal Agents; Biopsy; Chronic Disease; Diagnosis, Differential; Follow-Up Studies; Humans; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Remission Induction; Skin; Time Factors | 2008 |
A case of erysipeloid cutaneous leishmaniasis: atypical and unusual clinical variant.
Topics: Aged; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2008 |
[Sporotrichoid cutaneous leishmaniasis in Tunisia: a clinical and histological study].
Topics: Adult; Aged; Anti-Infective Agents; Antiprotozoal Agents; Female; Histiocytes; Humans; Leg Dermatoses; Leishmaniasis, Cutaneous; Lymphocytes; Male; Meglumine; Meglumine Antimoniate; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Sporotrichosis; Tunisia | 2008 |
[Glucantime reaction with fatal outcome following treatment of cutaneous leishmaniasis].
Topics: Aged; Antiprotozoal Agents; Fatal Outcome; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2008 |
Visceral leishmaniasis with cutaneous and rectal dissemination due to Leishmania braziliensis in acquired immunodeficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Antineoplastic Agents; Antiprotozoal Agents; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Recombinant Proteins; Rectal Diseases | 1995 |
Thermotherapy v. antimonials: what happens after the healing of cutaneous leishmaniasis lesions?
Topics: Animals; Antiprotozoal Agents; Disease Susceptibility; Female; Hyperthermia, Induced; Immunologic Memory; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Organometallic Compounds; Recurrence | 1993 |
Unusual association of American cutaneous leishmaniasis and acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antimony; Antiprotozoal Agents; Fatal Outcome; HIV Antibodies; Humans; Leishmania; Leishmania braziliensis; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 1996 |
Disseminated American cutaneous leishmaniasis.
Topics: Adolescent; Adult; Animals; Antimony; Antiprotozoal Agents; Azure Stains; Biopsy; Child; Cricetinae; Culture Media; Cytodiagnosis; Drug Administration Schedule; Drug Resistance; Female; Histiocytes; Humans; Injections, Intradermal; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Skin Tests; Skin Ulcer; Venezuela | 1996 |
In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.
Topics: 4-Quinolones; Administration, Oral; Animals; Anti-Infective Agents; Antiprotozoal Agents; Female; Injections, Subcutaneous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Plant Extracts; Plants, Medicinal | 1996 |
T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
Topics: Animals; Antigens, Protozoan; Antimony; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Female; Humans; Interferon-gamma; Interleukin-2; Interleukin-4; Leishmania; Leishmania braziliensis; Leishmaniasis, Cutaneous; Lymphocyte Activation; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; T-Lymphocytes | 1996 |
Old-world leishmaniasis of the auricle.
Topics: Adult; Antimony; Antiprotozoal Agents; Ear Diseases; Ear, External; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1997 |
[Postkala-azar dermal leishmaniasis].
Topics: Animals; Antiprotozoal Agents; Child; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1997 |
Cutaneous leishmaniasis in the Peruvian Andes: factors associated with variability in clinical symptoms, response to treatment, and parasite isolation rate.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antiprotozoal Agents; Arm; Child; Disease Transmission, Infectious; Female; Head; Host-Parasite Interactions; Humans; Immunity, Active; Insect Control; Leg; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Multivariate Analysis; Occupational Diseases; Organometallic Compounds; Peru; Psychodidae | 1997 |
Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antiprotozoal Agents; Blotting, Western; Colombia; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Molecular Weight; Organometallic Compounds; Sensitivity and Specificity | 1997 |
T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia.
Topics: Adult; Animals; Antigens, Protozoan; Antiprotozoal Agents; Brazil; Cell Division; Female; Humans; Interferon-gamma; Leishmania; Leishmaniasis, Cutaneous; Leukocytes, Mononuclear; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Protozoan Vaccines; Species Specificity; T-Lymphocytes | 1998 |
Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Infant; Injections, Intralesional; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 1998 |
Effects of antimonial therapy on serum zinc, copper and iron concentrations in patients with cutaneous Leishmaniasis in Turkey.
Topics: Adolescent; Adult; Antimony; Antiprotozoal Agents; Child; Copper; Humans; Iron; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Trace Elements; Turkey; Zinc | 1998 |
Follicular mucinosis associated with cutaneous leishmaniasis.
Topics: Antiprotozoal Agents; Biopsy, Needle; Disease-Free Survival; Female; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Middle Aged; Mucinosis, Follicular; Organometallic Compounds | 1998 |
South American cutaneous leishmaniasis: report of ten cases in Israeli travelers.
Topics: Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Female; Headache; Humans; Israel; Leg Ulcer; Leishmania mexicana; Leishmaniasis, Cutaneous; Liver; Liver Function Tests; Male; Meglumine; Meglumine Antimoniate; Muscle Weakness; Muscular Diseases; Organometallic Compounds; Pain; Retrospective Studies; Skin; South America; Travel; Weight Loss | 1998 |
Leishmaniasis recidiva cutis in New World cutaneous leishmaniasis.
Topics: Adult; Animals; Antiprotozoal Agents; Biopsy; DNA, Protozoan; Female; Humans; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Skin | 1998 |
Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Leishmania; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1999 |
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Topics: Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antiprotozoal Agents; Benzethonium; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Infusions, Parenteral; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Treatment Failure; Wound Healing | 1999 |
PCR follow-up examination after treatment of canine leishmaniosis (CaL).
Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Follow-Up Studies; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; Sensitivity and Specificity; Species Specificity | 1998 |
Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; BCG Vaccine; Cell Division; Combined Modality Therapy; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-5; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Lymphocyte Activation; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Mycobacterium bovis; Organometallic Compounds; Protozoan Vaccines; T-Lymphocytes, Helper-Inducer; Th1 Cells; Tuberculin | 2000 |
Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mexico; Middle Aged; Organometallic Compounds; Treatment Outcome | 1999 |
American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment.
Topics: Adolescent; Adult; Age Distribution; Analysis of Variance; Antiprotozoal Agents; Brazil; Child; Child, Preschool; Cohort Studies; Evaluation Studies as Topic; Female; Humans; Incidence; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Sensitivity and Specificity; Sex Distribution; Skin Tests | 2000 |
Garlic induces a shift in cytokine pattern in Leishmania major-infected BALB/c mice.
Topics: Adjuvants, Immunologic; Animals; Antiprotozoal Agents; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Garlic; Interferon-gamma; Interleukin-10; Interleukin-2; Interleukin-4; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Phytotherapy; Plants, Medicinal; Th1 Cells; Th2 Cells | 2000 |
A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate.
Topics: Administration, Topical; Antiprotozoal Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Plant Extracts; Randomized Controlled Trials as Topic; Treatment Outcome | 2000 |
[Epidemics of cutaneous leishmaniasis in military personnel working in French Guiana].
Topics: Antiprotozoal Agents; Bedding and Linens; Clothing; French Guiana; Humans; Insect Repellents; Insecticides; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Pentamidine; Recurrence; Skin; Trees | 2000 |
Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment.
Topics: Adult; Animals; Antigens, Protozoan; Antimony; Antiprotozoal Agents; Cytokines; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-10; Leishmania; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Protozoan Vaccines | 2001 |
[Effect of intralesional treatment with emetine hydrochloride on Leishmania (Viannia) braziliensis in hamsters].
Topics: Animals; Antiprotozoal Agents; Cicatrix; Cricetinae; Cytoplasm; Disease Reservoirs; Drug Evaluation, Preclinical; Emetine; Immunoenzyme Techniques; Injections, Intralesional; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Microscopy, Electron; Organometallic Compounds; Vacuoles | 2001 |
[Infiltrated cutaneous leishmaniasis and sporotrichosis caused by Leishmania major. First Senegalese case].
Topics: Adult; Animals; Diagnosis, Differential; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Senegal; Sporotrichosis | 2001 |
[N-methyl glucamine antimoniate or Glucantime].
Topics: Antiprotozoal Agents; Drug Interactions; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Patient Selection; Treatment Outcome | 2000 |
Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Follow-Up Studies; Humans; Leishmania braziliensis; Leishmania guyanensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prognosis | 2001 |
The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador.
Topics: Adolescent; Adult; Antiprotozoal Agents; Data Interpretation, Statistical; Ecuador; Female; Health Knowledge, Attitudes, Practice; Humans; Leishmaniasis, Cutaneous; Male; Medicine, Traditional; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Rural Population; Socioeconomic Factors | 2001 |
PCR detection of specific Leishmania-DNA in patients with periodontal disease.
Topics: Adult; Animals; Antiprotozoal Agents; Chronic Disease; DNA, Protozoan; Female; Gingiva; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Monocytes; Organometallic Compounds; Periodontitis; Polymerase Chain Reaction; Radiography; Venezuela | 2002 |
An outbreak of cutaneous leishmaniasis among soldiers in Belém, Pará State, Brazil, caused by Leishmania (Viannia) lindenbergi n. sp. A new leishmanial parasite of man in the Amazon region.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Protozoan; Antigens, Protozoan; Antiprotozoal Agents; Brazil; Disease Outbreaks; Female; Humans; Insect Vectors; Isoenzymes; Leishmania; Leishmaniasis, Cutaneous; Male; Mefloquine; Meglumine; Meglumine Antimoniate; Military Personnel; Organometallic Compounds; Protozoan Proteins; Psychodidae; Trees | 2002 |
[Cutaneous leishmaniasis of the lid].
Topics: Adult; Biopsy, Needle; Diagnosis, Differential; Eyelid Diseases; Female; Humans; Inflammation; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds | 2002 |
American cutaneous leishmaniasis as a rare imported disease in Europe: a case report favourably treated with antimonial derivatives.
Topics: Adolescent; Antiprotozoal Agents; Brazil; Diagnosis, Differential; Humans; Italy; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Travel | 2001 |
Effect of natural naphthoquinones in BALB/c mice infected with Leishmania amazonensis and L. venezuelensis.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Naphthoquinones; Organometallic Compounds; Plant Extracts | 1992 |
Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania; Leishmania braziliensis; Leishmania mexicana; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1992 |
Visceral and cutaneous leishmaniasis in an European paediatric population.
Topics: Animals; Antiprotozoal Agents; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentamidine | 1992 |
Oriental sore: a case report.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Lip Diseases; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 1992 |